EXPLORE MORE CATEGORIES
- Home
- »
- Our Products
- »
- Anti Cancer Injection - 1
Anti Cancer Injection - 1
Offering you a complete choice of products which include rascase rasburicase 1.5mg injection, ixabepilone injection(ixempra 45mg injection), inferject 500mg injection, zoldonat zoledronic acid 4mg injection, rituximab mabtas 100mg injection and gemcitabine gemtero 1gm injection.
Rascase Rasburicase 1.5mg Injection
Product Price: Rs 750 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Packaging Type | Vial |
| Strength | 1.5 mg |
| Pack Size | 1 Injection in 1 Vial |
| Compposition | Rasburicase 1.5 mg (r-DNA Origin) |
| Brand | Rascase 1.5 mg |
| Manufacturer | Sayre Therapeutics Pvt Ltd |
| Treatment | High uric acid due to chemotherapy |
Overview
Rascase (Rasburicase) 1.5 mg Injection is a recombinant urate oxidase enzyme used primarily to manage hyperuricemia associated with tumor lysis syndrome (TLS) in patients with hematological malignancies. By facilitating the breakdown of uric acid, Rascase plays a crucial role in preventing complications during cancer treatment.
Indications for Use
Rascase is primarily indicated for:
- Tumor Lysis Syndrome (TLS): Effective in the rapid management of elevated uric acid levels in patients undergoing chemotherapy for lymphoproliferative disorders, particularly in cases with a high risk of TLS.
Mechanism of Action
Rasburicase catalyzes the conversion of uric acid into allantoin, a more soluble compound that is easily excreted by the kidneys. By lowering uric acid levels in the blood, it helps prevent the complications associated with TLS, such as acute kidney injury and metabolic disturbances.
Dosage and Administration
The typical dosage of Rascase Rasburicase 1.5 mg Injection is determined by the healthcare provider based on the patient’s uric acid levels and specific clinical scenario. It is administered as a single intravenous infusion over 30 minutes. Regular monitoring of uric acid levels is essential to ensure effective treatment and adjust dosing if necessary.
Potential Side Effects
Common side effects may include:
Injection Site Reactions: Patients may experience localized pain, redness, or swelling at the injection site.
Gastrointestinal Distress: Some may report nausea or diarrhea following administration.
Allergic Reactions: Rarely, severe allergic reactions may occur, requiring immediate medical attention.
Serious side effects can include hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating appropriate screening prior to treatment.
Storage Instructions
Store Rascase Rasburicase 1.5 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Proper storage is critical to maintaining the medication’s efficacy until it is administered.
Patient Counseling Information
Patients receiving Rascase should be counseled to:
Report Side Effects: Advise patients to notify their healthcare provider of any unusual reactions or symptoms after administration.
Understand the Importance of Monitoring: Emphasize the need for regular monitoring of uric acid levels and kidney function to evaluate treatment effectiveness.
Stay Hydrated: Encourage adequate fluid intake to support kidney function and overall health during treatment.
Conclusion
Rascase Rasburicase 1.5 mg Injection is a vital treatment option for managing hyperuricemia associated with tumor lysis syndrome in cancer patients. By effectively reducing uric acid levels, it helps prevent serious complications during chemotherapy. Proper administration, ongoing monitoring, and patient education are essential for optimizing treatment outcomes and minimizing potential adverse effects. Open communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Ixabepilone Injection(Ixempra 45mg Injection)
Product Price: Rs 55,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 45 mg |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Ixabepilone 45mg |
| Brand | Ixempra 45mg |
| Manufacturer | BMS India Pvt Ltd |
| Treatment | Breast cancer |
Overview
Ixabepilone (Ixempra) 45 mg Injection is an innovative chemotherapeutic agent used primarily in the treatment of metastatic or locally advanced breast cancer. It belongs to a class of drugs known as epothilones, which function by stabilizing microtubules, thus disrupting normal cellular functions and inhibiting cancer cell division.
Indications for Use
Ixabepilone is indicated for:
- Metastatic Breast Cancer: Specifically for patients whose cancer has progressed after anthracycline and taxane chemotherapy, including those with triple-negative breast cancer.
Mechanism of Action
Ixabepilone exerts its anticancer effects by binding to β-tubulin and stabilizing the microtubule structure, which prevents the disassembly necessary for cell division. This stabilization leads to cell cycle arrest and ultimately results in apoptosis (programmed cell death) of cancer cells. Its unique mechanism makes it effective in tumors resistant to other forms of chemotherapy.
Dosage and Administration
The recommended dosage of Ixabepilone (Ixempra) 45 mg Injection is typically administered as a 1-hour intravenous infusion every three weeks. Dosage adjustments may be necessary based on the patient's individual response, tolerability, and specific side effects experienced. It is important to administer the drug under the supervision of a qualified healthcare professional.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Patients may experience gastrointestinal disturbances, which can often be managed with appropriate antiemetics.
- Fatigue: Many patients report feeling tired or weak during treatment.
- Peripheral Neuropathy: Tingling, numbness, or pain in the hands and feet may occur due to nerve damage.
Serious side effects can include:
- Bone Marrow Suppression: This can lead to decreased blood cell counts, increasing the risk of infections and bleeding.
- Hypersensitivity Reactions: Some patients may experience allergic reactions, requiring immediate medical attention.
Storage Instructions
Store Ixabepilone (Ixempra) 45 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure that the medication is kept out of reach of children.
Patient Counseling Information
Patients receiving Ixabepilone should be counseled to:
- Report Side Effects: Advise them to notify their healthcare provider of any unusual reactions, especially neurological symptoms or signs of infection.
- Hydration: Encourage adequate fluid intake to help manage side effects and maintain overall health.
- Regular Monitoring: Emphasize the importance of regular blood tests to monitor blood counts and liver function throughout treatment.
Conclusion
Ixabepilone (Ixempra) 45 mg Injection offers a valuable treatment option for patients with advanced breast cancer, particularly those with treatment-resistant forms of the disease. By effectively targeting cancer cell division, it plays a crucial role in improving patient outcomes. Proper administration, monitoring, and patient education are essential for maximizing the benefits of therapy while minimizing potential adverse effects. Open communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
Inferject 500mg injection
Product Price: Rs 3,000 / PieceGet Best Price
Minimum Order Quantity: 10 Piece
Product Brochure
Product Details:
| Strength | 500 mg |
| Pack Size | 10 ml in 1 Vial |
| Composition | Ferric Carboxymaltose 50mg |
| Brand Name | Inferject 500 mg/10 ml |
| Manufactured by | Vifor Pharma |
| Treatment | Lack of iron sickliness |
Overview
Inferject (Meropenem) 500 mg Injection is a broad-spectrum antibiotic used in the treatment of various serious bacterial infections. As a member of the carbapenem class of antibiotics, Inferject is effective against a wide range of gram-positive and gram-negative bacteria, making it an essential option in clinical settings where resistant organisms are a concern.
Indications for Use
Inferject is primarily indicated for:
-
Complicated Intra-Abdominal Infections: Effective in treating infections resulting from appendicitis, diverticulitis, and peritonitis.
-
Complicated Skin and Soft Tissue Infections: Utilized for severe infections of the skin or underlying tissues caused by susceptible organisms.
-
Pneumonia: Used in the management of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
-
Bacterial Meningitis: Sometimes indicated for the treatment of bacterial meningitis caused by susceptible pathogens.
Mechanism of Action
Meropenem, the active ingredient in Inferject 500 mg Injection, works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), disrupting the final stages of peptidoglycan synthesis, leading to cell lysis and death. Its broad-spectrum activity allows it to effectively combat both aerobic and anaerobic bacteria.
Dosage and Administration
The recommended dosage of Inferject 500 mg Injection varies depending on the type and severity of the infection, as well as the patient’s renal function. It is typically administered intravenously, with dosing schedules ranging from every 8 hours to once a day. Healthcare providers should assess individual patient needs to determine the appropriate regimen.
Potential Side Effects
Common side effects may include:
-
Nausea and Vomiting: Gastrointestinal disturbances are commonly reported.
-
Diarrhea: This may occur due to alterations in gut flora.
-
Injection Site Reactions: Local pain, swelling, or redness at the injection site may be experienced.
-
Allergic Reactions: Rarely, severe allergic reactions can occur, necessitating immediate medical attention.
Serious side effects may include seizures, particularly in patients with a history of seizure disorders or renal impairment.
Storage Instructions
Store Inferject 500 mg Injection in a cool, dry place, protected from light. Follow specific storage guidelines provided by the manufacturer to maintain the medication's effectiveness prior to administration.
Patient Counseling Information
Patients receiving Inferject should be counseled to:
-
Report Side Effects: Advise patients to inform their healthcare provider of any unusual reactions or symptoms following administration.
-
Complete the Course: Emphasize the importance of completing the full course of treatment, even if symptoms improve, to prevent the development of antibiotic resistance.
-
Stay Hydrated: Encourage adequate fluid intake to help manage potential side effects and maintain overall health.
Conclusion
Inferject 500 mg Injection is a critical treatment option for serious bacterial infections, offering broad-spectrum efficacy against a variety of pathogens. Proper administration, ongoing monitoring, and patient education are essential for optimizing treatment outcomes and minimizing potential adverse effects. Open communication between patients and healthcare providers is vital for successful infection management.
Yes! I am InterestedRequest A Callback
Zoldonat Zoledronic Acid 4mg Injection
Product Price: Rs 1,500 / PieceGet Best Price
Minimum Order Quantity: 10 Piece
Product Brochure
Product Details:
| Dose/Strength | 4 mg |
| Packaging Type | Vial |
| Composition | Zoledronic Acid 4 mg |
| Brand Name | Zoldonat 4 mg |
| Manufacturer/Marketer | Natco Pharma Ltd |
| Treatment | Osteoporosis |
Overview
Zoldonat (Zoledronic Acid) 4 mg Injection is a bisphosphonate used primarily to treat bone complications associated with cancer. It is effective in preventing skeletal-related events (SREs) such as fractures, spinal cord compression, and the need for radiation therapy or surgery in patients with metastatic bone disease. Zoldonat is also indicated for the treatment of hypercalcemia of malignancy.
Indications for Use
Zoldonat is indicated for:
- Prevention of Skeletal-Related Events: In patients with solid tumors that have metastasized to bone, including breast and prostate cancer.
- Hypercalcemia of Malignancy: Management of elevated calcium levels in patients with certain malignancies.
Mechanism of Action
Zoledronic acid acts by inhibiting osteoclast activity, which decreases bone resorption. This mechanism helps maintain bone density and strength, thereby reducing the risk of skeletal-related complications in cancer patients. By modulating bone metabolism, Zoldonat plays a critical role in the supportive care of oncology patients.
Dosage and Administration
The recommended dose of Zoldonat (Zoledronic Acid) 4 mg Injection is typically given as a single intravenous infusion over 15 minutes. For patients at risk of skeletal-related events due to bone metastases, the infusion is generally administered every 3 to 4 weeks. Prior to treatment, kidney function should be assessed, and renal parameters should be monitored throughout therapy.
Potential Side Effects
Common side effects may include:
- Flu-like Symptoms: Patients often experience mild fever, chills, fatigue, and muscle or joint pain after administration.
- Nausea: Some patients may have mild gastrointestinal upset.
- Bone Pain: Pain in affected bones may occur as the medication takes effect.
Serious side effects can include:
- Renal Impairment: Zoledronic acid may affect kidney function; regular monitoring is essential.
- Osteonecrosis of the Jaw: A rare but serious condition associated with bisphosphonate therapy, requiring vigilance, particularly in patients undergoing dental procedures.
Storage Instructions
Store Zoldonat (Zoledronic Acid) 4 mg Injection at room temperature, protected from light and moisture. It should not be frozen. Follow manufacturer guidelines for optimal storage conditions to maintain efficacy.
Patient Counseling Information
Patients receiving Zoldonat should be counseled to:
- Report Side Effects: Inform healthcare providers of any unusual symptoms, especially signs of renal issues or jaw pain.
- Stay Hydrated: Adequate hydration is important before and after the infusion to help support kidney function.
- Routine Monitoring: Emphasize the need for regular blood tests to monitor kidney health and calcium levels.
Conclusion
Zoldonat (Zoledronic Acid) 4 mg Injection is an essential treatment option for managing bone health in cancer patients, significantly reducing the risk of skeletal-related events. Its efficacy and targeted mechanism make it a vital part of supportive oncology care. Proper administration, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is key to successful cancer management.
Yes! I am InterestedRequest A Callback
Rituximab Mabtas 100mg Injection
Product Price: Rs 4,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Size | 10 ml |
| Dose/Strength | 10 mg/ml |
| Composition | Rituximab 100mg |
| Brand Name | Mabtas 100 |
| Manufactured by | Intas Pharmaceuticals Ltd |
| Treatment | Non-Hodgkin lymphoma (NHL),Rheumatoid arthritis,Blood cancer (Chronic lymphocytic leukemia) |
Overview
Mabtas (Rituximab) 100 mg Injection is a monoclonal antibody designed for treating hematologic malignancies and autoimmune diseases. By targeting the CD20 antigen on B-cells, Mabtas effectively manages conditions such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). This innovative therapy enhances treatment efficacy and may have fewer side effects than traditional chemotherapy.
Indications for Use
Mabtas is indicated for:
Non-Hodgkin Lymphoma (NHL): Effective for various subtypes, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
Chronic Lymphocytic Leukemia (CLL): Used alongside chemotherapy to improve treatment outcomes.
Rheumatoid Arthritis: For moderate to severe cases unresponsive to other therapies, helping to reduce inflammation.
Granulomatosis with Polyangiitis: Employed with other medications to manage this serious autoimmune condition.
Mechanism of Action
Rituximab binds to the CD20 protein on B-cells, leading to their destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This targeted action helps manage both malignant and autoimmune disorders while sparing healthy cells.
Dosage and Administration
The dosage of Mabtas Rituximab 100 mg Injection varies by condition. For NHL, the typical initial dose is an intravenous infusion of 375 mg/m² on the first day, followed by maintenance doses based on patient response. Healthcare providers will tailor the schedule to individual needs.
Potential Side Effects
Common side effects may include:
Infusion-Related Reactions: Fever, chills, and hypotension during or after infusion.
Fatigue: Patients may feel tired or weak after treatment.
Nausea and Vomiting: Gastrointestinal upset may occur but is usually manageable.
Infection Risk: B-cell depletion can increase susceptibility to infections, requiring careful monitoring.
Serious side effects can include severe allergic reactions and progressive multifocal leukoencephalopathy (PML), necessitating vigilant oversight by healthcare providers.
Storage Instructions
Store Mabtas Rituximab 100 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze, as proper storage is crucial for maintaining the medication's effectiveness.
Patient Counseling Information
Patients should be advised to:
Report Side Effects: Notify healthcare providers of unusual symptoms, especially during infusions.
Understand Treatment Protocol: Emphasize adherence to the prescribed regimen and the importance of follow-up appointments.
Practice Infection Precautions: Educate on good hygiene to reduce infection risks during treatment.
Conclusion
Mabtas Rituximab 100 mg Injection is an essential option for managing non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders. Its targeted action enhances patient outcomes while minimizing side effects. Proper administration, monitoring, and patient education are vital for maximizing treatment benefits. Open communication between patients and healthcare providers is key to effective management.
Yes! I am InterestedRequest A Callback
Gemcitabine Gemtero 1gm injection
Product Price: Rs 1,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Dose/Strength | 1000 mg |
| Packaging Type | Vial |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Gemcitabine 1g |
| Brand Name | Gemtero |
| Manufactured by | Hetero Drugs Ltd |
Overview
Gemcitabine (Gemtero) 1 gm Injection is a potent chemotherapy agent used in the treatment of several types of cancer. As a nucleoside analog, it interferes with DNA synthesis and inhibits cancer cell growth. This medication is essential in oncology, providing effective treatment options for patients with specific malignancies.
Indications for Use
Gemcitabine is indicated for:
Non-Small Cell Lung Cancer (NSCLC): Often used as part of combination therapy to enhance treatment outcomes in advanced stages.
Pancreatic Cancer: Effective in managing metastatic pancreatic cancer, improving survival rates when combined with other agents.
Breast Cancer: Used in specific regimens for patients with metastatic disease, particularly when other treatments have failed.
Bladder Cancer: Administered as part of a treatment regimen for advanced bladder cancer.
Mechanism of Action
Gemcitabine works by mimicking nucleosides required for DNA synthesis, thereby interfering with the cancer cell’s ability to replicate. Once incorporated into DNA, it disrupts normal functioning, leading to apoptosis and slowing tumor growth.
Dosage and Administration
The typical dosage of Gemcitabine (Gemtero) 1 gm Injection varies based on cancer type and patient health. Commonly, it is administered via intravenous infusion, with schedules ranging from weekly to bi-weekly. Healthcare providers determine the exact dosage based on patient response.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: Patients may experience gastrointestinal disturbances, often manageable with antiemetics.
Fatigue: A common side effect, fatigue may impact daily activities.
Bone Marrow Suppression: This can lead to decreased blood cell counts, increasing the risk of infections, anemia, and bleeding.
Skin Reactions: Patients may develop rashes or skin irritations at the injection site.
Serious side effects can include liver enzyme abnormalities and severe allergic reactions. Regular monitoring of blood counts and liver function is essential during treatment.
Storage Instructions
Store Gemcitabine (Gemtero) 1 gm Injection in a cool, dry place, protected from light. Refrigerate at 2°C to 8°C (36°F to 46°F) to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Gemcitabine should be advised to:
Report Side Effects: Notify healthcare providers of unusual or severe symptoms, particularly affecting blood counts or liver function.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments.
Maintain Hydration: Encourage patients to stay well-hydrated, especially if they experience gastrointestinal side effects.
Conclusion
Gemcitabine (Gemtero) 1 gm Injection is a vital treatment for various cancers, including non-small cell lung cancer, pancreatic cancer, and bladder cancer. Its effectiveness in inhibiting cancer cell growth makes it a cornerstone in chemotherapy regimens. Proper administration, monitoring, and patient education are crucial for maximizing the benefits of this medication. Effective communication between patients and healthcare providers ensures optimal management of cancer treatment.
Yes! I am InterestedRequest A Callback
Endoxan N 500 Mg Injection
Product Price: Rs 135 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 500 mg |
| Form | Injection |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Cyclophosphamide 500 mg |
| Brand | Endoxan - N 500 mg |
| Manufacturer | Baxter International |
| Treatment | Cancer and nephrotic syndrome (kidney disease) |
Overview
Endoxan (Cyclophosphamide) 500 mg Injection is an effective chemotherapy agent widely used in oncology for various cancers and autoimmune disorders. As an alkylating agent, it interferes with DNA synthesis, inhibiting cancer cell growth and promoting cell death. This makes Endoxan a critical component in many cancer treatment regimens.
Indications for Use
Endoxan is indicated for:
Breast Cancer: Often part of combination therapy for managing early and metastatic breast cancer.
Non-Hodgkin Lymphoma: Effective in treating various types of lymphoma, especially when combined with other agents.
Leukemias: Utilized in the treatment of acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Autoimmune Disorders: Used in conditions like lupus and rheumatoid arthritis to suppress the immune system.
Mechanism of Action
Cyclophosphamide is a prodrug converted in the liver to active metabolites. These metabolites form covalent bonds with DNA, leading to cross-linking of DNA strands. This disruption in replication and repair processes results in apoptosis of rapidly dividing cells, including cancerous and certain immune cells.
Dosage and Administration
The dosage of Endoxan (Cyclophosphamide) 500 mg Injection is determined by the healthcare provider based on the specific condition, patient’s age, and overall health. It is typically administered intravenously, with dosing schedules varying from weekly to bi-weekly, depending on the treatment protocol.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: Patients often experience gastrointestinal disturbances, manageable with antiemetics.
Bone Marrow Suppression: This can lead to decreased white blood cell counts, increasing the risk of infections and bleeding.
Fatigue: A common side effect that may significantly impact daily life.
Hair Loss: Temporary alopecia may occur during treatment.
Serious side effects can include bladder toxicity, hemorrhagic cystitis, and increased risk of secondary malignancies. Regular monitoring of blood counts and bladder function is essential.
Storage Instructions
Store Endoxan (Cyclophosphamide) 500 mg Injection in a cool, dry place, protected from light. Refrigerate at 2°C to 8°C (36°F to 46°F) to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Endoxan should be counseled to:
Report Side Effects: Notify healthcare providers of any unusual symptoms, particularly those affecting blood counts or bladder health.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments.
Stay Hydrated: Encourage adequate fluid intake to help mitigate bladder toxicity.
Conclusion
Endoxan (Cyclophosphamide) 500 mg Injection is a vital treatment option for various cancers and autoimmune disorders. Its ability to inhibit cancer cell growth and modulate the immune response makes it essential in many treatment protocols. Proper administration, monitoring, and patient education are crucial for maximizing the benefits of this medication. Effective communication between patients and healthcare providers is key to optimal cancer management.
Yes! I am InterestedRequest A Callback
Endoxan 1 Gm Injection
Product Price: Rs 300 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 1 g |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Cyclophosphamide 1g |
| Brand | Endoxan 1g |
| Manufacturer | Baxter International |
| Treatment | Cancer,Nephrotic syndrome |
Overview
Endoxan (Cyclophosphamide) 1 gm Injection is a powerful chemotherapy agent utilized in oncology for treating various cancers and certain autoimmune disorders. As an alkylating agent, it interferes with DNA synthesis, inhibiting cancer cell growth and promoting cell death. Endoxan plays a critical role in many cancer treatment protocols, providing effective management options.
Indications for Use
Endoxan is indicated for:
Breast Cancer: Often used as part of combination therapy for both early and metastatic cases.
Non-Hodgkin Lymphoma: Effective in treating various subtypes, especially when combined with other chemotherapeutic agents.
Leukemias: Employed in the treatment of acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Autoimmune Disorders: Used in conditions like lupus and rheumatoid arthritis to help suppress the immune response.
Mechanism of Action
Cyclophosphamide is a prodrug that converts in the liver to active metabolites. These metabolites bind covalently to DNA, causing cross-linking of DNA strands. This interference disrupts DNA replication and repair, leading to apoptosis (programmed cell death) of rapidly dividing cells, including cancerous and certain immune cells.
Dosage and Administration
The dosage of Endoxan (Cyclophosphamide) 1 gm Injection is tailored by healthcare providers based on the specific condition, patient age, and overall health status. It is typically administered via intravenous infusion, with dosing schedules often ranging from weekly to bi-weekly, according to the treatment protocol.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: Gastrointestinal disturbances are common but can often be managed with antiemetics.
Bone Marrow Suppression: This can lead to reduced white blood cell counts, increasing the risk of infections and bleeding tendencies.
Fatigue: Patients frequently report fatigue, which can significantly impact daily life.
Alopecia: Temporary hair loss may occur during treatment.
Serious side effects can include bladder toxicity, hemorrhagic cystitis, and a potential increased risk of secondary malignancies. Regular monitoring of blood counts and bladder function is crucial during treatment.
Storage Instructions
Store Endoxan (Cyclophosphamide) 1 gm Injection in a cool, dry place, protected from light. It should be refrigerated at 2°C to 8°C (36°F to 46°F) to maintain its stability and effectiveness.
Patient Counseling Information
Patients receiving Endoxan should be advised to:
Report Side Effects: Notify healthcare providers of any unusual symptoms, especially those affecting blood counts or bladder health.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments.
Stay Hydrated: Encourage adequate fluid intake to help mitigate potential bladder toxicity.
Conclusion
Endoxan (Cyclophosphamide) 1 gm Injection is a crucial treatment option for various cancers and autoimmune disorders. Its ability to inhibit cancer cell growth and modulate immune responses makes it an essential part of many treatment protocols. Proper administration, monitoring, and patient education are vital for maximizing the benefits of this medication. Effective communication between patients and healthcare providers is key to ensuring optimal cancer management.
Yes! I am InterestedRequest A Callback
Taceedo 120 mg Injection
Product Price: Rs 5,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 120 mg |
| Pack Size | 3 ml |
| Manufactured by | Miracalus Pharma Pvt Ltd |
| Composition | Docetaxel 120 mg/3 ml |
| Brand | Taceedo 120 mg |
| Treatment | Breast cancer,Non-small cell lung cancer,Prostate cancer |
Overview
Taceedo (Trastuzumab) 120 mg Injection is a monoclonal antibody specifically designed for the treatment of HER2-positive cancers, including certain types of breast and gastric cancers. By targeting the HER2 protein, Taceedo effectively inhibits cancer cell growth, making it a vital component of targeted therapy in oncology.
Indications for Use
Taceedo is indicated for:
HER2-Positive Breast Cancer: Used in both adjuvant (post-surgery) and metastatic settings to improve survival rates and reduce recurrence.
Gastric Cancer: Effective in combination with chemotherapy for treating HER2-positive gastric and gastroesophageal junction cancers.
Mechanism of Action
Taceedo works by binding to the HER2 receptor on the surface of cancer cells. This binding blocks the receptor's activation and subsequent signaling pathways that promote cell proliferation and survival. Additionally, it marks cancer cells for destruction by the immune system, enhancing the body’s ability to fight the tumor.
Dosage and Administration
The dosage of Taceedo (Trastuzumab) 120 mg Injection is determined by the healthcare provider based on the patient's weight and specific treatment protocol. It is typically administered via intravenous infusion. The initial dose may be higher, followed by maintenance doses given at regular intervals.
Potential Side Effects
Common side effects may include:
Infusion Reactions: Patients may experience fever, chills, and nausea during or shortly after the infusion.
Cardiovascular Effects: Monitoring for heart function is essential, as trastuzumab can lead to heart failure in some patients.
Fatigue: Many patients report feeling tired during treatment.
Rash: Skin reactions may occur, typically mild to moderate in severity.
Serious side effects can include severe allergic reactions and significant heart problems, making regular monitoring vital throughout treatment.
Storage Instructions
Store Taceedo (Trastuzumab) 120 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure that the medication is kept in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Taceedo should be advised to:
Report Side Effects: Notify healthcare providers of any unusual reactions, especially cardiovascular symptoms.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments.
Stay Hydrated: Encourage adequate fluid intake before and after infusion.
Conclusion
Taceedo (Trastuzumab) 120 mg Injection is a critical treatment option for patients with HER2-positive cancers, particularly breast and gastric cancers. Its targeted approach significantly enhances treatment effectiveness and patient outcomes. Proper administration, monitoring, and patient education are essential for maximizing the benefits of this therapy. Effective communication between patients and healthcare providers is vital to ensuring optimal cancer management.
Yes! I am InterestedRequest A Callback
Krabeva 400 mg Injection
Product Price: Rs 17,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Pack Type | 1 Injection in 1 Vial |
| Compostion | Bevacizumab 400 mg |
| Brand Name | Krabeva 400 mg |
| Manufacturer | Biocon |
| Treatment | Colon and rectum Cancer,Ovarian cancer,Cervical cancer,Kidney cancer,Brain tumor |
Overview
Krabeva (Bevacizumab) 400 mg Injection is a monoclonal antibody used as a targeted therapy for various types of cancers. By inhibiting vascular endothelial growth factor (VEGF), Krabeva plays a crucial role in preventing tumor growth and metastasis by blocking the formation of new blood vessels (angiogenesis) that supply tumors with the necessary nutrients and oxygen.
Indications for Use
Krabeva is indicated for:
Colorectal Cancer: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer.
Non-Small Cell Lung Cancer (NSCLC): Effective in combination with chemotherapy for patients with advanced NSCLC.
Renal Cell Carcinoma: Utilized in treating advanced renal cell carcinoma in conjunction with other therapies.
Glioblastoma: Indicated for patients with recurrent glioblastoma, aiding in disease management.
Mechanism of Action
Krabeva works by binding to VEGF, preventing it from interacting with its receptors on the surface of endothelial cells. This action inhibits the signaling pathways that promote blood vessel formation. By disrupting the supply of blood to tumors, Krabeva effectively slows tumor growth and can lead to reduced tumor size and improved patient outcomes.
Dosage and Administration
The dosage of Krabeva (Bevacizumab) 400 mg Injection is determined by the healthcare provider based on the type of cancer, treatment protocol, and patient characteristics. It is typically administered via intravenous infusion. Dosing schedules can vary, often every two to three weeks, depending on the specific treatment regimen.
Potential Side Effects
Common side effects may include:
Hypertension: Patients may experience elevated blood pressure, which should be monitored regularly.
Fatigue: Many patients report tiredness during treatment.
Gastrointestinal Issues: Nausea, vomiting, and diarrhea may occur.
Wound Healing Complications: Delayed healing may be observed, particularly in patients undergoing surgery.
Serious side effects can include severe allergic reactions, gastrointestinal perforations, and thromboembolic events, making regular monitoring essential during treatment.
Storage Instructions
Store Krabeva (Bevacizumab) 400 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Krabeva should be counseled to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially those related to blood pressure or gastrointestinal issues.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments.
Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Krabeva (Bevacizumab) 400 mg Injection is a crucial targeted therapy for various cancers, including colorectal, lung, and renal cell carcinomas. Its ability to inhibit angiogenesis significantly enhances treatment outcomes. Proper administration, monitoring, and patient education are vital for maximizing the benefits of this therapy. Effective communication between patients and healthcare providers is essential for optimal cancer management.
Yes! I am InterestedRequest A Callback
Krabeva 100 Mg Injection
Product Price: Rs 8,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 100 mg/4 ml |
| Brand | Krabeva 100 Mg |
| Pack Typ | 4 ml in 1 Vial |
| Composition | Bevacizumab 100 mg |
| Manufacturer | Biocon |
| Treatment | Colon and rectum Cancer,Ovarian cancer,Cervical cancer,Kidney cancer,Brain tumor |
Overview
Krabeva (Bevacizumab) 100 mg Injection is a monoclonal antibody used in targeted cancer therapy. By inhibiting vascular endothelial growth factor (VEGF), Krabeva effectively disrupts the process of angiogenesis, which is crucial for tumor growth and metastasis. This makes it an essential treatment option for various malignancies.
Indications for Use
Krabeva is indicated for:
Metastatic Colorectal Cancer: Often used in combination with chemotherapy regimens to enhance treatment effectiveness.
Non-Small Cell Lung Cancer (NSCLC): Administered with chemotherapy for patients with advanced stages of NSCLC.
Renal Cell Carcinoma: Used as part of the treatment for advanced renal cell carcinoma in conjunction with other therapies.
Glioblastoma: Indicated for patients with recurrent glioblastoma, assisting in disease management.
Mechanism of Action
Krabeva works by binding to VEGF, preventing it from interacting with its receptors on endothelial cells. This blockade inhibits the signaling pathways responsible for new blood vessel formation. By restricting blood supply to tumors, Krabeva slows tumor growth and can lead to reduced tumor size, enhancing overall patient outcomes.
Dosage and Administration
The dosage of Krabeva (Bevacizumab) 100 mg Injection is tailored to each patient based on cancer type, treatment protocol, and individual health status. It is typically administered via intravenous infusion, with schedules varying from every two to three weeks, depending on the specific cancer treatment plan.
Potential Side Effects
Common side effects may include:
Hypertension: Regular monitoring of blood pressure is essential, as patients may experience elevated levels.
Fatigue: Many patients report increased tiredness during treatment.
Gastrointestinal Symptoms: Nausea, vomiting, and diarrhea can occur.
Delayed Wound Healing: Patients undergoing surgery may experience complications related to healing.
Serious side effects can include severe allergic reactions, gastrointestinal perforations, and thromboembolic events. Regular monitoring and communication with healthcare providers are crucial to managing these risks.
Storage Instructions
Store Krabeva (Bevacizumab) 100 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to ensure stability.
Patient Counseling Information
Patients receiving Krabeva should be advised to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially those related to blood pressure or gastrointestinal distress.
Adhere to Treatment: Stress the importance of following the prescribed regimen and attending all scheduled appointments for monitoring.
Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Krabeva (Bevacizumab) 100 mg Injection is a vital component of targeted cancer therapy for various malignancies, including colorectal, lung, and renal cancers. By inhibiting angiogenesis, it significantly improves treatment outcomes. Proper administration, monitoring, and patient education are essential for maximizing therapeutic benefits. Effective communication between patients and healthcare providers is key to ensuring optimal cancer management.
Yes! I am InterestedRequest A Callback
Kemocarb 450 Mg Injection
Product Price: Rs 750 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Dose/Strength | 450 mg |
| Packaging Size | 45 ml |
| Composition | Carboplatin 450 mg |
| Brand Name | Kemocarb 45 ml |
| Manufacturer | Fresenius Kabi India Pvt Ltd |
| Treatment | Ovarian cancer,Small cell lung cancer |
Overview
Kemocarb (Carmustine) 450 mg Injection is a potent alkylating agent used in chemotherapy for various cancers. It is particularly effective against brain tumors and other malignancies due to its ability to penetrate the blood-brain barrier, making it an invaluable tool in oncology.
Indications for Use
Kemocarb is indicated for:
Brain Tumors: Primarily used in the treatment of gliomas, including glioblastoma multiforme, either alone or in combination with other therapies.
Multiple Myeloma: Utilized as part of a combination chemotherapy regimen for patients with multiple myeloma.
Lymphomas: Effective in treating certain types of lymphoma, including Hodgkin's and non-Hodgkin's lymphoma.
Mechanism of Action
Carmustine acts as an alkylating agent, which means it binds to DNA and forms cross-links that prevent DNA replication and transcription. This mechanism leads to cell cycle arrest and ultimately triggers apoptosis (programmed cell death) in cancer cells. Its ability to cross the blood-brain barrier is particularly beneficial for treating central nervous system tumors.
Dosage and Administration
The dosage of Kemocarb (Carmustine) 450 mg Injection is determined by the healthcare provider based on cancer type, treatment protocol, and patient factors. It is typically administered intravenously. Dosing schedules often vary, generally occurring every 6 to 8 weeks to allow for recovery from side effects.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: These symptoms can usually be managed with appropriate antiemetics.
Bone Marrow Suppression: Patients may experience decreases in white blood cells, red blood cells, and platelets, increasing the risk of infections and bleeding.
Pulmonary Toxicity: Long-term use can lead to lung damage, which should be monitored carefully.
Skin Reactions: Injection site reactions may occur, as well as other dermatological issues.
Serious side effects can include severe allergic reactions and liver toxicity, necessitating regular monitoring of liver function and blood counts.
Storage Instructions
Store Kemocarb (Carmustine) 450 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure the medication remains in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Kemocarb should be advised to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly respiratory issues or signs of infection.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments for monitoring.
Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Kemocarb (Carmustine) 450 mg Injection is an essential chemotherapy agent for various cancers, especially brain tumors and multiple myeloma. Its unique ability to cross the blood-brain barrier enhances its effectiveness in treating central nervous system malignancies. Proper administration, monitoring, and patient education are vital for maximizing treatment outcomes. Effective communication between patients and healthcare providers is crucial for optimal cancer care.
Yes! I am InterestedRequest A Callback
Fluracil 250 Mg Injection
Product Price: Rs 50 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 250 mg |
| Pack Size | 5 ml in 1 Vial |
| Composition | Fluorouracil 250 mg |
| Brand Name | Fluracil 250 mg |
| Manufactured by | Biochem Pharmaceutical Industries |
| Treatment | Cancer |
Overview
Fluracil (Fluorouracil) 250 mg Injection is a vital antimetabolite chemotherapy agent used primarily for treating various cancers. It interferes with DNA and RNA synthesis, making it effective against rapidly dividing cancer cells.
Indications for Use
Fluracil is indicated for:
Colorectal Cancer: Used in both adjuvant and metastatic settings to enhance treatment outcomes.
Gastric Cancer: Effective in combination with other agents for gastric tumors.
Breast Cancer: Utilized in combination regimens for advanced cases.
Head and Neck Cancers: Employed in managing specific malignancies in this region.
Mechanism of Action
Fluorouracil acts as an antimetabolite by inhibiting thymidylate synthase, an enzyme crucial for DNA synthesis. This disruption prevents the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), leading to reduced thymidine levels, impaired DNA replication, and promoting apoptosis (programmed cell death) in cancer cells.
Dosage and Administration
The dosage of Fluracil (Fluorouracil) 250 mg Injection is tailored to individual patients based on cancer type, treatment response, and overall health. It is administered intravenously, typically as a continuous infusion or in bolus doses. Dosing schedules may vary, often repeated every few weeks depending on the specific treatment protocol.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: Patients may experience gastrointestinal distress, which can often be managed with antiemetics.
Bone Marrow Suppression: This may lead to decreased white blood cell, red blood cell, and platelet counts, increasing infection and bleeding risks.
Stomatitis: Inflammation of the mouth’s mucous membranes may lead to discomfort.
Hand-Foot Syndrome: Patients may experience redness, swelling, and pain in the palms and soles.
Serious side effects can include severe allergic reactions and significant liver toxicity, necessitating regular monitoring of liver function and blood counts during treatment.
Storage Instructions
Store Fluracil (Fluorouracil) 250 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Fluracil should be advised to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly gastrointestinal distress or signs of infection.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled follow-up appointments.
Maintain Hydration: Encourage adequate fluid intake and a balanced diet to support overall health during treatment.
Conclusion
Fluracil (Fluorouracil) 250 mg Injection is a critical component in managing various cancers, including colorectal and gastric cancers. Its ability to inhibit DNA synthesis makes it a valuable treatment option. Proper administration, monitoring, and patient education are essential for maximizing therapeutic benefits. Effective communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Bleocel 15 IU Injection
Product Price: Rs 350 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Dose/Strength | 15 Units |
| Packaging Type | Box |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Bleomycin 15 IU |
| Brand Name | Bleocel 15 |
| Manufactured by | Celon Laboratories Pvt Ltd |
| Treatment | Head and neck Cancer,cervix and external genitalia,lymph node cancer |
Overview
Bleocel (Bleomycin) 15 IU Injection is a potent anticancer medication used primarily in chemotherapy protocols. It is derived from the bacterium Streptomyces verticillus and is known for its effectiveness in treating various malignancies, particularly in combination with other chemotherapeutic agents.
Indications for Use
Bleocel is indicated for:
Testicular Cancer: Utilized in the treatment of germ cell tumors, often as part of a combination therapy.
Hodgkin's Lymphoma: Employed in combination regimens for managing this type of lymphoma.
Non-Hodgkin's Lymphoma: Effective in treating certain subtypes of non-Hodgkin's lymphoma.
Skin Cancers: Used in the treatment of specific skin cancers, including squamous cell carcinoma.
Mechanism of Action
Bleomycin exerts its anticancer effects through several mechanisms. It binds to DNA, causing strand breaks that impede DNA replication and transcription. This leads to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cancer cells. Additionally, it generates free radicals that contribute to its cytotoxic effects.
Dosage and Administration
The dosage of Bleocel (Bleomycin) 15 IU Injection is determined by the healthcare provider based on the type of cancer, stage, and individual patient factors. It is typically administered intravenously, intramuscularly, or subcutaneously, depending on the treatment protocol. Dosing schedules may vary, often given in cycles to allow recovery from side effects.
Potential Side Effects
Common side effects may include:
Fever and Chills: Patients may experience flu-like symptoms following administration.
Skin Reactions: Dermatological side effects such as rash, erythema, or hyperpigmentation may occur.
Pulmonary Toxicity: Long-term use can lead to lung damage, necessitating regular monitoring of respiratory function.
Nausea and Vomiting: These symptoms can often be managed with appropriate antiemetics.
Serious side effects can include severe allergic reactions and significant pulmonary complications, emphasizing the need for close monitoring throughout treatment.
Storage Instructions
Store Bleocel (Bleomycin) 15 IU Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Bleocel should be counseled to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly respiratory issues or severe skin reactions.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled appointments for monitoring.
Avoid Vaccinations: Patients should discuss any planned vaccinations with their healthcare provider, as live vaccines may pose risks during treatment.
Conclusion
Bleocel (Bleomycin) 15 IU Injection is a vital component in the management of various cancers, particularly testicular and Hodgkin's lymphoma. Its unique mechanism of action and effectiveness in combination therapies make it a valuable treatment option. Proper administration, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Effective communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Abingem 200 Mg Injection
Product Price: Rs 350 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Dose/Strength | 200 mg |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Gemcitabine 200 mg |
| Brand Name | Abingem 200mg |
| Manufactured by | Miracalus Pharma Pvt Ltd |
| Treatment | Breast Cancer,Pancreatic Cancer,Non-small-cell Lung Cancer,Bladder Cancer,and Ovarian Cancer |
Overview
Abingem (Gemcitabine) 200 mg Injection is a potent chemotherapy drug used primarily in the treatment of various cancers. As an antimetabolite, it interferes with the synthesis of DNA, making it effective against rapidly dividing cancer cells.
Indications for Use
Abingem is indicated for:
Pancreatic Cancer: Utilized in both adjuvant and metastatic settings, improving patient outcomes.
Non-Small Cell Lung Cancer (NSCLC): Often used in combination with other chemotherapy agents for enhanced efficacy.
Bladder Cancer: Effective as a part of combination therapy for advanced cases.
Breast Cancer: Sometimes used in specific regimens for treatment.
Mechanism of Action
Gemcitabine is incorporated into the DNA of cancer cells, inhibiting their ability to replicate. It works by blocking the enzyme ribonucleotide reductase, leading to reduced deoxynucleotide pools essential for DNA synthesis. This disruption ultimately results in cell cycle arrest and apoptosis (programmed cell death) of cancer cells.
Dosage and Administration
The dosage of Abingem (Gemcitabine) 200 mg Injection is individualized based on the type of cancer, stage, and overall patient health. It is typically administered intravenously, with dosing cycles often repeated every one to three weeks, depending on the treatment protocol. Close monitoring is essential to evaluate treatment effectiveness and manage side effects.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: These symptoms can be managed with antiemetic medications.
Bone Marrow Suppression: This can lead to decreased white blood cell, red blood cell, and platelet counts, increasing the risk of infections and bleeding.
Fatigue: Many patients experience fatigue during treatment, which may impact daily activities.
Hair Loss: Temporary hair loss may occur, which usually resolves after the treatment ends.
Serious side effects can include severe allergic reactions and pulmonary toxicity, necessitating careful monitoring during therapy.
Storage Instructions
Store Abingem (Gemcitabine) 200 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to ensure stability.
Patient Counseling Information
Patients receiving Abingem should be counseled to:
Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly related to gastrointestinal distress or signs of infection.
Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all scheduled follow-up appointments.
Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Abingem (Gemcitabine) 200 mg Injection is a critical component in the management of various cancers, including pancreatic and non-small cell lung cancer. Its mechanism of action and effectiveness in combination therapies make it a valuable treatment option. Proper administration, monitoring, and patient education are essential for optimizing treatment outcomes and minimizing adverse effects. Effective communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
Abingem 1gm Injection
Product Price: Rs 900 / BoxGet Best Price
Minimum Order Quantity: 10 Box
Product Brochure
Product Details:
| Dose/Strength | 1000 mg |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Gemcitabine 1 gm |
| Brand Name | Abingem 1gm |
| Manufactured by | Miracalus Pharma Pvt Ltd |
| Treatment | Breast Cancer,Pancreatic Cancer,Non-small-cell Lung Cancer,Bladder Cancer,and Ovarian Cancer |
Overview
Abingem (Gemcitabine) 1 gm Injection is a powerful chemotherapy medication used in the treatment of various cancers. As an antimetabolite, it interferes with DNA synthesis, making it particularly effective against rapidly dividing cancer cells.
Indications for Use
Abingem is indicated for:
- Pancreatic Cancer: Used in both adjuvant and metastatic settings to improve overall survival rates.
- Non-Small Cell Lung Cancer (NSCLC): Often administered in combination with other chemotherapy agents to enhance therapeutic efficacy.
- Bladder Cancer: Effective in the management of advanced stages as part of combination therapy.
- Breast Cancer: Utilized in specific treatment regimens for advanced disease.
Mechanism of Action
Gemcitabine is incorporated into the DNA of cancer cells, inhibiting their ability to replicate. It functions by blocking the enzyme ribonucleotide reductase, leading to a reduction in the availability of deoxynucleotides necessary for DNA synthesis. This disruption results in cell cycle arrest and apoptosis (programmed cell death) of malignant cells.
Dosage and Administration
The dosage of Abingem (Gemcitabine) 1 gm Injection is individualized based on the type of cancer, stage, and the patient’s overall health. It is typically administered intravenously, with treatment cycles generally repeated every one to three weeks, depending on the specific protocol. Close monitoring is essential to assess treatment efficacy and manage any potential side effects.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: These symptoms are often manageable with antiemetic medications.
- Bone Marrow Suppression: Can lead to decreased white blood cell, red blood cell, and platelet counts, increasing the risk of infections and bleeding.
- Fatigue: A common occurrence that may significantly impact a patient’s daily activities.
- Hair Loss: Temporary hair loss is a possible side effect, which typically resolves after the completion of treatment.
Serious side effects may include severe allergic reactions, pulmonary toxicity, and the potential for significant bleeding complications, necessitating vigilant monitoring during therapy.
Storage Instructions
Store Abingem (Gemcitabine) 1 gm Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Abingem should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly gastrointestinal distress or signs of infection.
- Adhere to Treatment: Highlight the importance of following the prescribed treatment regimen and attending all scheduled follow-up appointments.
- Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Abingem (Gemcitabine) 1 gm Injection is a vital component in the management of various cancers, including pancreatic and non-small cell lung cancer. Its effectiveness in combination therapies makes it a valuable treatment option. Proper administration, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Taceedo 80 Mg Injection
Product Price: Rs 1,050 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 80 mg |
| Pack Size | 2 ml |
| Pack-Type | 1 Injection in 1 Vial |
| Composition | Docetaxel 80mg |
| Brand | Taceedo 80 mg |
| Manufactured by | Miracalus Pharma Pvt Ltd |
| Treatment | Breast cancer,Non-small cell lung cancer,Prostate cancer |
Overview
Taceedo (Docetaxel) 80 mg Injection is a powerful chemotherapy medication primarily used to treat various cancers. As a taxane, it disrupts cell division by interfering with the microtubule structure, making it effective against rapidly dividing cancer cells.
Indications for Use
Taceedo is indicated for:
- Breast Cancer: Employed in both adjuvant and metastatic settings to enhance patient survival rates.
- Non-Small Cell Lung Cancer (NSCLC): Often used in combination with other chemotherapeutic agents for increased efficacy.
- Prostate Cancer: Utilized in the treatment of hormone-refractory metastatic prostate cancer.
- Head and Neck Cancer: Effective as part of a combination regimen for advanced stages.
Mechanism of Action
Docetaxel binds to tubulin, a key protein that forms microtubules necessary for cell division. By stabilizing these microtubules and preventing their disassembly, Docetaxel halts normal mitotic processes, leading to cell cycle arrest and apoptosis (programmed cell death) in cancer cells.
Dosage and Administration
The dosage of Taceedo (Docetaxel) 80 mg Injection is tailored to the patient's cancer type, stage, and overall health. It is administered intravenously, with treatment cycles typically repeated every three weeks. Healthcare providers will closely monitor patients to assess treatment effectiveness and manage any side effects.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Often manageable with antiemetic medications.
- Bone Marrow Suppression: Can lead to reduced blood cell counts, increasing the risk of infections and bleeding.
- Fatigue: A frequent occurrence that may impact the patient’s quality of life.
- Fluid Retention: Some patients may experience swelling due to fluid accumulation.
Serious side effects can include severe allergic reactions, peripheral neuropathy, and pulmonary complications, necessitating careful monitoring during treatment.
Storage Instructions
Store Taceedo (Docetaxel) 80 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep the medication in its original packaging until use to maintain its stability.
Patient Counseling Information
Patients receiving Taceedo should be counseled to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially gastrointestinal distress or signs of infection.
- Adhere to Treatment: Stress the importance of following the prescribed regimen and attending all follow-up appointments.
- Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Taceedo (Docetaxel) 80 mg Injection is a vital treatment option in oncology, effective against various cancers, including breast and non-small cell lung cancer. Proper administration, monitoring, and patient education are essential for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Vinelbine 50mg Injection
Product Price: Rs 7,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 50 mg |
| Packaging Size | 5 ml |
| Composition | Vinorelbine 50 mg |
| Brand | Vinelbine 50 mg |
| Manufacturer | Fresenius Kabi India Pvt Ltd |
| Treatment | Breast cancer,Non-small cell lung cancer |
Overview
Vinelbine (Vinorelbine) 50 mg Injection is an important chemotherapy medication used in the treatment of various cancers, primarily non-small cell lung cancer (NSCLC) and breast cancer. As a vinca alkaloid, it disrupts the process of cell division, making it effective against rapidly dividing cancer cells.
Indications for Use
Vinelbine is indicated for:
- Non-Small Cell Lung Cancer (NSCLC): Commonly used in both advanced and metastatic cases, often in combination with other chemotherapeutic agents.
- Breast Cancer: Effective in the treatment of advanced breast cancer, especially when previous therapies have failed.
Mechanism of Action
Vinorelbine works by inhibiting the polymerization of tubulin, a protein essential for the formation of microtubules. This disruption leads to the blockage of the cell cycle during mitosis, causing cancer cells to undergo apoptosis (programmed cell death). By preventing proper cell division, Vinorelbine effectively reduces tumor growth and spread.
Dosage and Administration
The dosage of Vinelbine (Vinorelbine) 50 mg Injection is tailored to each patient based on their cancer type, stage, and overall health. It is typically administered intravenously, with treatment cycles repeated every one to three weeks. Healthcare providers will monitor patients closely to evaluate the effectiveness of the treatment and to manage any potential side effects.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Often manageable with supportive care and antiemetic medications.
- Bone Marrow Suppression: Leading to decreased white blood cell, red blood cell, and platelet counts, increasing the risk of infections and bleeding.
- Fatigue: A frequent issue that can significantly impact daily activities and quality of life.
- Neuropathy: Some patients may experience numbness or tingling in the hands and feet.
Serious side effects can include severe allergic reactions, liver toxicity, and respiratory issues, necessitating careful monitoring during therapy.
Storage Instructions
Store Vinelbine (Vinorelbine) 50 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Vinelbine should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially related to gastrointestinal distress or signs of infection.
- Adhere to Treatment: Emphasize the importance of following the prescribed treatment regimen and attending all follow-up appointments.
- Maintain Hydration: Encourage adequate fluid intake to help support overall health during treatment.
Conclusion
Vinelbine (Vinorelbine) 50 mg Injection is a critical option in the management of various cancers, particularly non-small cell lung cancer and breast cancer. Effective administration, monitoring, and patient education are essential for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is vital for successful cancer care.
Yes! I am InterestedRequest A Callback
Vinelbine 10mg Injection
Product Price: Rs 4,100 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 10 mg |
| Packaging Size | 1 ml |
| Composition | Vinorelbine 10mg |
| Brand | Vinelbine 10mg |
| Manufacturer | Fresenius Kabi India Pvt Ltd |
| Treatment | Breast cancer,Non-small cell lung cancer |
Overview
Vinelbine (Vinorelbine) 10 mg Injection is a significant chemotherapy medication primarily used in the treatment of various cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. As a vinca alkaloid, it disrupts cell division, making it effective against rapidly proliferating cancer cells.
Indications for Use
Vinelbine is indicated for:
- Non-Small Cell Lung Cancer (NSCLC): Commonly utilized in both advanced and metastatic cases, often in combination with other chemotherapeutic agents.
- Breast Cancer: Effective in the management of advanced breast cancer, especially when other treatments have not yielded results.
Mechanism of Action
Vinorelbine acts by inhibiting the polymerization of tubulin, a crucial protein needed for the formation of microtubules. This disruption blocks the cell cycle during mitosis, leading to apoptosis (programmed cell death) in cancer cells. By preventing proper cell division, Vinorelbine effectively reduces tumor growth and metastasis.
Dosage and Administration
The dosage of Vinelbine (Vinorelbine) 10 mg Injection is individualized based on the specific type and stage of cancer, as well as the patient's overall health. It is typically administered intravenously, with treatment cycles repeated every one to three weeks. Close monitoring by healthcare providers is essential to evaluate treatment efficacy and manage any potential side effects.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: These can often be managed with antiemetic medications.
- Bone Marrow Suppression: Leading to decreased white blood cell, red blood cell, and platelet counts, which increases the risk of infections and bleeding.
- Fatigue: Many patients experience fatigue that may impact their quality of life.
- Peripheral Neuropathy: Some patients may notice numbness or tingling in their extremities.
Serious side effects can include severe allergic reactions, liver toxicity, and respiratory complications, necessitating careful monitoring during treatment.
Storage Instructions
Store Vinelbine (Vinorelbine) 10 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain its stability and effectiveness.
Patient Counseling Information
Patients receiving Vinelbine should be counseled to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly gastrointestinal distress or signs of infection.
- Adhere to Treatment: Stress the importance of following the prescribed treatment regimen and attending all follow-up appointments.
- Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Vinelbine (Vinorelbine) 10 mg Injection is a vital treatment option in oncology, particularly for non-small cell lung cancer and breast cancer. Proper administration, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Taceedo 20 Mg Injection
Product Price: Rs 550 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 20 mg |
| Pack Size | 0.5 ml |
| Composition | Docetaxel 20 mg |
| Brand | Taceedo 20 |
| Manufactured by | Miracalus Pharma Pvt Ltd |
| Treatment | Breast cancer,Non-small cell lung cancer,Prostate cancer |
Overview
Taceedo (Docetaxel) 20 mg Injection is a potent chemotherapy medication widely used in oncology to treat various cancers, particularly breast cancer, non-small cell lung cancer (NSCLC), and prostate cancer. As a taxane, it interferes with the normal function of microtubules, thereby inhibiting cancer cell division and promoting apoptosis (programmed cell death).
Indications for Use
Taceedo is indicated for:
- Breast Cancer: Utilized in both adjuvant and metastatic settings, often in combination with other chemotherapy agents.
- Non-Small Cell Lung Cancer (NSCLC): Effective in advanced stages, frequently used alongside other medications.
- Prostate Cancer: Used for hormone-refractory metastatic cases, providing significant therapeutic benefits.
- Head and Neck Cancers: Employed as part of combination regimens for advanced disease management.
Mechanism of Action
Docetaxel functions by binding to tubulin, a key protein that forms microtubules, which are critical for cell division. By stabilizing these microtubules, Docetaxel prevents their disassembly, effectively blocking the mitotic spindle function during cell division. This disruption leads to cell cycle arrest and apoptosis, contributing to reduced tumor growth.
Dosage and Administration
The dosage of Taceedo (Docetaxel) 20 mg Injection is tailored to each patient's specific cancer type, stage, and overall health status. It is administered intravenously, usually every three weeks. Healthcare providers will closely monitor patients to evaluate the treatment's effectiveness and manage potential side effects.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Often manageable with antiemetic therapy.
- Bone Marrow Suppression: May result in decreased blood cell counts, raising the risk of infections and bleeding.
- Fatigue: A common complaint that can significantly affect daily life.
- Fluid Retention: Patients may experience swelling due to fluid accumulation.
Serious side effects can include severe allergic reactions, pulmonary toxicity, and liver function abnormalities, necessitating careful monitoring during treatment.
Storage Instructions
Store Taceedo (Docetaxel) 20 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Taceedo should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially gastrointestinal distress or signs of infection.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Maintain Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Taceedo (Docetaxel) 20 mg Injection is a crucial treatment option in the management of various cancers, particularly breast and non-small cell lung cancer. Proper administration, monitoring, and patient education are vital for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Mabtas 500 Mg Infusion
Product Price: Rs 9,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 500 mg |
| Packaging Type | Bottle |
| Packaging Size | 50 ml |
| Composition | Rituximab 500 mg/50 ml |
| Brand Name | Mabtas 500 |
| Manufactured by | Intas Pharmaceuticals Ltd |
| Treatment | Non-Hodgkin lymphoma (NHL),Rheumatoid arthritis,Blood cancer (Chronic lymphocytic leukemia) |
Overview
Mabtas (Rituximab) 500 mg Infusion is a monoclonal antibody used in the treatment of various hematological malignancies and certain autoimmune disorders. As a targeted therapy, it specifically binds to the CD20 protein found on the surface of B-cells, leading to cell death and a reduction in the number of malignant B-cells.
Indications for Use
Mabtas is indicated for:
- Non-Hodgkin Lymphoma (NHL): Effective in treating various forms of NHL, particularly when used in combination with chemotherapy.
- Chronic Lymphocytic Leukemia (CLL): Used in combination with fludarabine and cyclophosphamide for patients with CLL.
- Rheumatoid Arthritis: Indicated for patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs).
- Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Used for the treatment of these severe autoimmune conditions.
Mechanism of Action
Rituximab works by selectively binding to the CD20 antigen on B-cells. This binding triggers multiple mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis (cell death) of the B-cells. This targeted approach helps in reducing the malignant B-cell population while sparing other cells, leading to fewer side effects compared to traditional chemotherapies.
Dosage and Administration
The dosage of Mabtas (Rituximab) 500 mg Infusion is determined by the specific condition being treated and the patient's body surface area. It is typically administered as an intravenous infusion, with the initial infusion given slowly to monitor for any infusion-related reactions. Subsequent doses may be administered more rapidly, depending on the patient's tolerance.
Potential Side Effects
Common side effects may include:
- Infusion Reactions: Symptoms such as fever, chills, and nausea may occur during or after infusion.
- Infections: Increased risk of infections due to B-cell depletion.
- Fatigue: A common side effect that may impact daily activities.
- Rash: Skin reactions can occur in some patients.
Serious side effects can include severe allergic reactions, reactivation of hepatitis B virus, and cardiac events, necessitating careful monitoring during treatment.
Storage Instructions
Store Mabtas (Rituximab) 500 mg Infusion in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain its stability and effectiveness.
Patient Counseling Information
Patients receiving Mabtas should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly infusion reactions or signs of infection.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage regular blood tests to monitor for potential infections and overall health.
Conclusion
Mabtas (Rituximab) 500 mg Infusion represents a critical advancement in the treatment of hematological cancers and autoimmune disorders. Proper administration, monitoring, and patient education are essential for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is vital for successful management.
Yes! I am InterestedRequest A Callback
Canmab Trastuzumab 440 Mg Injection
Product Price: Rs 18,000 / BoxGet Best Price
Minimum Order Quantity: 10 Box
Product Brochure
Product Details:
| Strength | 440 mg |
| Pack Type | 1 injection in 1 Vial |
| Composition | Trastuzumab 440mg |
| Brand | Canmab 440 mg |
| Manufacturer | Biocon |
| Treatment | Breast cancer,Stomach cancer |
Overview
Canmab (Trastuzumab) 440 mg Injection is a monoclonal antibody used in the treatment of HER2-positive breast cancer and gastric cancer. By specifically targeting the human epidermal growth factor receptor 2 (HER2), Canmab plays a crucial role in inhibiting the growth of cancer cells that overexpress this protein, providing a targeted therapeutic approach.
Indications for Use
Canmab is indicated for:
- Breast Cancer: Effective in both early-stage and metastatic HER2-positive breast cancer, often used in combination with chemotherapy or as adjuvant therapy.
- Gastric Cancer: Indicated for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, typically used in combination with other chemotherapeutic agents.
Mechanism of Action
Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells. This binding blocks the receptor's ability to activate cell proliferation and survival pathways, leading to decreased tumor growth. Additionally, it mediates antibody-dependent cellular cytotoxicity (ADCC), enhancing the immune system’s ability to target and eliminate HER2-overexpressing cells.
Dosage and Administration
The dosage of Canmab (Trastuzumab) 440 mg Injection is tailored to the individual patient based on their specific cancer type, stage, and treatment history. It is administered via intravenous infusion, typically every three weeks. Healthcare professionals will monitor patients for any infusion-related reactions and adjust treatment as necessary.
Potential Side Effects
Common side effects may include:
- Infusion Reactions: Symptoms such as fever, chills, and nausea may occur during or shortly after infusion.
- Cardiovascular Effects: Patients may experience heart-related issues, including decreased left ventricular function, necessitating cardiac monitoring.
- Fatigue: A common side effect that can impact daily activities.
- Nausea and Vomiting: Gastrointestinal symptoms can occur but are often manageable with supportive care.
Serious side effects can include severe allergic reactions, pulmonary toxicity, and heart failure, highlighting the importance of close monitoring during treatment.
Storage Instructions
Store Canmab (Trastuzumab) 440 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to ensure its stability and effectiveness.
Patient Counseling Information
Patients receiving Canmab should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly infusion reactions or heart-related issues.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage routine cardiac evaluations and reporting any changes in health status.
Conclusion
Canmab (Trastuzumab) 440 mg Injection is a vital treatment option for HER2-positive breast and gastric cancers, offering targeted therapy that can significantly improve patient outcomes. Proper administration, monitoring, and patient education are essential for optimizing treatment efficacy and minimizing adverse effects. Open communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Canmab 150 mg Trastuzumab Injection
Product Price: Rs 8,500 / PieceGet Best Price
Minimum Order Quantity: 10 Piece
Product Brochure
Product Details:
| Strength | 150 mg |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Trastuzumab 150mg |
| Brand | Canmab 150mg |
| Manufacturer | Biocon |
| Treatment | Breast cancer |
Overview
Canmab (Trastuzumab) 150 mg Injection is a monoclonal antibody designed for the treatment of HER2-positive breast cancer and gastric cancer. By specifically targeting the human epidermal growth factor receptor 2 (HER2), Canmab plays a crucial role in inhibiting the growth of cancer cells that overexpress this receptor, providing a targeted therapeutic approach that enhances patient outcomes.
Indications for Use
Canmab is indicated for:
- Breast Cancer: Effective in the treatment of both early-stage and metastatic HER2-positive breast cancer, often used in conjunction with chemotherapy or as adjuvant therapy.
- Gastric Cancer: Indicated for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, typically as part of a combination treatment regimen.
Mechanism of Action
Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells, blocking the receptor's ability to activate cell proliferation and survival pathways. This inhibition leads to reduced tumor growth. Additionally, it enhances the immune system's ability to eliminate HER2-overexpressing cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC).
Dosage and Administration
The dosage of Canmab (Trastuzumab) 150 mg Injection is tailored based on the individual patient’s cancer type, stage, and previous treatment history. It is administered via intravenous infusion, typically every week or every three weeks, depending on the treatment protocol. Healthcare professionals will monitor patients closely for infusion-related reactions and adjust treatment as necessary.
Potential Side Effects
Common side effects may include:
- Infusion Reactions: Symptoms such as fever, chills, and nausea may occur during or shortly after the infusion.
- Cardiovascular Effects: Patients may experience heart-related issues, including decreased left ventricular function, which necessitates cardiac monitoring.
- Fatigue: A common side effect that may affect daily activities.
- Gastrointestinal Symptoms: Nausea and vomiting may occur but are often manageable with supportive care.
Serious side effects can include severe allergic reactions, pulmonary toxicity, and heart failure, underscoring the importance of close monitoring during treatment.
Storage Instructions
Store Canmab (Trastuzumab) 150 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to ensure its stability and effectiveness.
Patient Counseling Information
Patients receiving Canmab should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly those related to infusion reactions or heart function.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage routine cardiac evaluations and the reporting of any changes in health status.
Conclusion
Canmab (Trastuzumab) 150 mg Injection represents a critical option in the targeted treatment of HER2-positive breast and gastric cancers. Proper administration, monitoring, and patient education are essential for optimizing treatment efficacy and minimizing adverse effects. Open communication between patients and healthcare providers is vital for effective cancer management.
Yes! I am InterestedRequest A Callback
Trastuzumab Injection (Vivitra 150mg Injection)
Product Price: Rs 12,000 / BoxGet Best Price
Minimum Order Quantity: 10 Box
Product Brochure
Product Details:
| Strength | 150 mg |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Trastuzumab Lyophilized Powder 150 mg |
| Brand | Vivitra 150mg |
| Manufacturer | Zydus Cadila |
| Treatment | Breast and stomach cancer |
Overview
Trastuzumab (Vivitra 150 mg Injection) is a monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2). It is primarily used in the treatment of HER2-positive breast cancer and gastric cancer. By blocking the HER2 receptor, Vivitra helps inhibit cancer cell growth and promotes the immune system's ability to attack tumor cells.
Indications for Use
Vivitra is indicated for:
- Breast Cancer: Effective in both early-stage and metastatic HER2-positive breast cancer, often used in conjunction with chemotherapy or as an adjuvant therapy following surgery.
- Gastric Cancer: Indicated for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, typically administered alongside other chemotherapeutic agents.
Mechanism of Action
Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells, inhibiting the receptor's activation, which is responsible for cell proliferation and survival. This mechanism not only reduces tumor growth but also mediates antibody-dependent cellular cytotoxicity (ADCC), enhancing the immune response against HER2-overexpressing cells.
Dosage and Administration
The dosage of Trastuzumab (Vivitra 150 mg Injection) is tailored to each patient based on their cancer type, stage, and treatment history. It is administered via intravenous infusion, typically given every week or every three weeks, depending on the treatment regimen. Healthcare professionals will closely monitor patients for infusion-related reactions and adjust treatment as necessary.
Potential Side Effects
Common side effects may include:
- Infusion Reactions: Symptoms such as fever, chills, and nausea may occur during or shortly after infusion.
- Cardiovascular Effects: Patients may experience decreased left ventricular function, necessitating regular cardiac monitoring.
- Fatigue: A common side effect that can significantly impact daily activities.
- Gastrointestinal Symptoms: Nausea and diarrhea may occur, but are often manageable.
Serious side effects can include severe allergic reactions, pulmonary toxicity, and heart failure, underscoring the importance of monitoring during treatment.
Storage Instructions
Store Trastuzumab (Vivitra 150 mg Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to ensure its stability and effectiveness.
Patient Counseling Information
Patients receiving Vivitra should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly those related to infusion reactions or heart function.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage routine cardiac evaluations and the reporting of any changes in health status.
Conclusion
Trastuzumab (Vivitra 150 mg Injection) represents a critical treatment option for HER2-positive breast and gastric cancers. Proper administration, monitoring, and patient education are essential for maximizing treatment efficacy and minimizing adverse effects. Open communication between patients and healthcare providers is vital for effective cancer management.
Yes! I am InterestedRequest A Callback
Erbitux 100 Mg Infusion
Product Price: Rs 10,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Prescription/Non prescription | Prescription |
| Country of Origin | Made in India |
| Dose/Strength | 100 mg/20 ml |
| Composition | Cetuximab 100 mg/20 ml |
| Brand | Erbitux 5mg/ml |
| Manufacturer | Merck Sereno |
| Treatment | Head and neck cancer,Cancer of colon and rectum |
Overview
Erbitux (Cetuximab) 100 mg Infusion is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of metastatic colorectal cancer and head and neck cancers. By inhibiting EGFR signaling, Erbitux helps to slow down the growth of cancer cells and enhances the effectiveness of chemotherapy and radiation therapy.
Indications for Use
Erbitux is indicated for:
- Metastatic Colorectal Cancer: Used in combination with chemotherapy for patients with EGFR-expressing tumors, particularly those who are not candidates for surgery.
- Head and Neck Cancer: Effective as part of the treatment regimen for patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Mechanism of Action
Cetuximab binds specifically to the extracellular domain of the EGFR, preventing the binding of natural ligands such as EGF and TGF-alpha. This blockade disrupts downstream signaling pathways that promote cell proliferation and survival, leading to reduced tumor growth and increased apoptosis. Additionally, Erbitux may enhance the effectiveness of radiation therapy by increasing tumor cell sensitivity to radiation.
Dosage and Administration
The dosage of Erbitux (Cetuximab) 100 mg Infusion is determined by the patient's body surface area and specific treatment protocol. It is typically administered as an intravenous infusion, starting with a loading dose followed by weekly maintenance doses. Patients are closely monitored for infusion-related reactions, particularly during the first administration.
Potential Side Effects
Common side effects may include:
- Infusion Reactions: Patients may experience fever, chills, and skin reactions during or shortly after the infusion.
- Skin Toxicity: Acneiform eruptions, dry skin, and other dermatological issues are frequently reported.
- Gastrointestinal Symptoms: Nausea and diarrhea can occur, requiring appropriate management.
- Fatigue: A common side effect that may impact daily activities.
Serious side effects can include severe allergic reactions, electrolyte imbalances, and cardiopulmonary complications, necessitating close monitoring during treatment.
Storage Instructions
Store Erbitux (Cetuximab) 100 mg Infusion in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain stability and effectiveness.
Patient Counseling Information
Patients receiving Erbitux should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, especially those related to skin reactions or infusion-related issues.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage routine blood tests to monitor electrolyte levels and overall health.
Conclusion
Erbitux (Cetuximab) 100 mg Infusion is a crucial treatment option for patients with EGFR-positive metastatic colorectal and head and neck cancers. Proper administration, monitoring, and patient education are essential for maximizing treatment efficacy and minimizing adverse effects. Open communication between patients and healthcare providers is vital for effective cancer management.
Yes! I am InterestedRequest A Callback
Cycloxan 1gm Injection
Product Price: Rs 120 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1 g |
| Prescription/Non prescription | Non prescription |
| Country of Origin | Made in India |
| Composition | Cyclophosphamide 1g |
| Brand | Cycloxan 1g |
| Manufacturer | Zydus Celexa |
| Treatment | Malignant lymphomas, Leukemias, Retinoblastoma, Carcinoma of breast, Ovarian cancer |
Overview
Cycloxan (Cyclophosphamide) 1 gm Injection is a potent alkylating agent used in chemotherapy. It is effective in treating a variety of cancers, including lymphomas, leukemias, and solid tumors. By interfering with the DNA synthesis process, Cyclophosphamide plays a crucial role in inhibiting the growth of cancer cells.
Indications for Use
Cycloxan is indicated for:
- Lymphomas: Utilized in the treatment of Hodgkin's and non-Hodgkin's lymphomas as part of combination therapy.
- Leukemias: Effective in managing acute and chronic leukemias.
- Breast Cancer: Often used in conjunction with other agents for metastatic breast cancer treatment.
- Ovarian Cancer: Administered in combination protocols for advanced ovarian cancer.
- Immunosuppressive Therapy: Used in conditions like severe autoimmune diseases and organ transplant preparation.
Mechanism of Action
Cyclophosphamide is converted into active metabolites that bind to DNA, forming cross-links that prevent the DNA strands from separating during replication. This mechanism inhibits cell division and leads to apoptosis (programmed cell death) in rapidly dividing cancer cells. The dual action of directly damaging DNA and inducing immune suppression makes it effective in various therapeutic contexts.
Dosage and Administration
The dosage of Cycloxan (Cyclophosphamide) 1 gm Injection is tailored to the individual based on the type of cancer, treatment protocol, and patient condition. It is typically administered via intravenous infusion. Pre-medication with antiemetic agents is often recommended to reduce potential nausea and vomiting.
Potential Side Effects
Common side effects may include:
- Bone Marrow Suppression: Leading to decreased white blood cell counts, which increases the risk of infections, anemia, and bleeding.
- Nausea and Vomiting: Commonly experienced, requiring supportive care.
- Fatigue: Many patients report significant tiredness during treatment.
- Hair Loss: Temporary hair loss can occur as a result of the treatment.
Serious side effects may include bladder toxicity, allergic reactions, and long-term risk of secondary malignancies. Regular monitoring is essential to manage these risks effectively.
Storage Instructions
Store Cycloxan (Cyclophosphamide) 1 gm Injection in a cool, dry place, away from light. Follow specific storage guidelines provided by the manufacturer to ensure the medication’s stability and effectiveness.
Patient Counseling Information
Patients receiving Cyclophosphamide should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe reactions, especially signs of infection or urinary changes.
- Regular Monitoring: Emphasize the importance of routine blood tests to monitor blood cell counts and kidney function.
- Hydration: Encourage adequate fluid intake to help prevent bladder toxicity and manage side effects.
Conclusion
Cycloxan (Cyclophosphamide) 1 gm Injection is a vital chemotherapy agent for treating various cancers, including lymphomas and breast cancer. Proper administration, monitoring, and patient education are essential for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is crucial for effective cancer management.
Yes! I am InterestedRequest A Callback
Pegasta 6 Mg Injection
Product Price: Rs 2,400 / BoxGet Best Price
Minimum Order Quantity: 10 Box
Product Brochure
Product Details:
| Packaging Size | 1X0.6 ml Vial |
| Strength | 6 mg/ 0.6 ml |
| Dose/Strength | 6 mg |
| Composition | Pegylated 6 mg r-Human Granulocyte Colony Stimulating Factor (rHU G-CSF) Injection |
| Brand | Pegasta 6 mg |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Uses | Prevention of infections after chemotherapy |
Overview
Pegasta (Pegfilgrastim) 6 mg Injection is a long-acting granulocyte colony-stimulating factor (G-CSF) that plays a vital role in supporting patients undergoing chemotherapy. By stimulating the bone marrow to produce white blood cells, Pegasta helps reduce the risk of infection associated with chemotherapy-induced neutropenia, improving patients' overall health and treatment outcomes.
Indications for Use
Pegasta is primarily indicated for:
- Prevention of Chemotherapy-Induced Neutropenia: It is used in patients receiving myelosuppressive chemotherapy for various cancers, including breast cancer and non-Hodgkin lymphoma.
- Support for Patients with Neutropenia: Pegasta can aid in the recovery of patients experiencing severe neutropenia due to chemotherapy or other medical conditions.
Mechanism of Action
Pegfilgrastim, the active ingredient in Pegasta, acts by binding to and activating the G-CSF receptor on hematopoietic cells. This stimulation promotes the proliferation, differentiation, and activation of neutrophil precursors, leading to an increase in the number of circulating neutrophils. By enhancing the body’s immune response, Pegasta significantly reduces the risk of infection during periods of low white blood cell counts.
Dosage and Administration
The recommended dose of Pegasta (Pegfilgrastim) 6 mg Injection is typically administered as a single subcutaneous injection per chemotherapy cycle, usually given at least 24 hours after chemotherapy. The dosage may vary based on individual patient factors, and healthcare providers will tailor the administration schedule accordingly.
Potential Side Effects
Common side effects may include:
- Bone Pain: Many patients report mild to moderate bone pain, which can often be managed with over-the-counter pain relief.
- Injection Site Reactions: Localized reactions such as redness, swelling, or pain may occur at the injection site.
- Fatigue: Some patients may experience general fatigue.
Serious side effects can include:
- Splenic Rupture: Rare cases of splenic rupture have been reported; patients should be advised to seek immediate medical attention for abdominal pain or discomfort.
- Allergic Reactions: Severe allergic reactions are rare but require immediate medical intervention.
Storage Instructions
Store Pegasta (Pegfilgrastim) 6 mg Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake the injection. Keep it protected from light and ensure it is out of reach of children.
Patient Counseling Information
Patients receiving Pegasta should be counseled to:
- Report Side Effects: Notify healthcare providers of any unusual symptoms, especially severe abdominal pain or signs of allergic reactions.
- Hydration: Encourage adequate fluid intake to support overall health during treatment.
- Regular Monitoring: Emphasize the importance of routine blood tests to monitor white blood cell counts and overall health.
Conclusion
Pegasta (Pegfilgrastim) 6 mg Injection is a critical supportive therapy for patients undergoing chemotherapy, effectively reducing the risk of neutropenia and its associated complications. Its targeted action and ease of administration make it an essential part of cancer care. Proper patient management, ongoing monitoring, and education are vital to maximizing treatment efficacy and minimizing side effects. Strong communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Avonex 30 Mcg Injection
Product Price: Rs 7,500 / PieceGet Best Price
Minimum Order Quantity: 10 Piece
Product Brochure
Product Details:
| Dose/Strength | 30 mcg/0.5 ml |
| Packaging Size | 0.5 ml Injection 1 Vial |
| Composition | Recombinant Human Interferon beta 1A (30 ug/0.5 ml) |
| Brand Name | Avonex 30 |
| Manufacturer | Biogenetic Pharmaceuticals |
| Treatment | Multiple sclerosis |
Overview
Avonex (Interferon Beta-1a) 30 mcg Injection is a biologic medication indicated for the treatment of relapsing forms of multiple sclerosis (MS). It is part of the interferon class of drugs, which work to modulate the immune system, reducing the frequency and severity of MS relapses.
Indications for Use
Avonex is primarily indicated for:
- Relapsing-Remitting Multiple Sclerosis (RRMS): Used to reduce the frequency of clinical exacerbations in patients with RRMS.
- Secondary Progressive Multiple Sclerosis (SPMS): It may also be used in patients with SPMS who experience occasional relapses.
Mechanism of Action
Interferon Beta-1a, the active ingredient in Avonex, acts on the immune system to reduce inflammation and modulate immune responses. By inhibiting the migration of immune cells into the central nervous system and decreasing the production of pro-inflammatory cytokines, it helps to protect nerve cells and reduce damage associated with MS.
Dosage and Administration
The recommended dosage of Avonex (Interferon Beta-1a) 30 mcg Injection is typically administered as a single dose once a week via intramuscular injection. Patients are encouraged to rotate injection sites to minimize local reactions. Proper training on injection techniques is essential for effective and safe administration.
Potential Side Effects
Common side effects may include:
- Flu-like Symptoms: Many patients experience symptoms such as fever, chills, fatigue, and muscle aches, particularly after the initial doses.
- Injection Site Reactions: Localized redness, swelling, or pain may occur at the injection site.
- Mood Changes: Some patients report mood swings or depressive symptoms during treatment.
Serious side effects can include:
- Allergic Reactions: Rare but potentially severe reactions may occur, including skin rashes or difficulty breathing.
- Liver Function Abnormalities: Regular monitoring of liver enzymes is advised, as Avonex may cause liver dysfunction.
Storage Instructions
Store Avonex (Interferon Beta-1a) 30 mcg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and ensure the medication is out of reach of children.
Patient Counseling Information
Patients receiving Avonex should be counseled to:
- Monitor Side Effects: Advise them to report any severe or persistent side effects, especially flu-like symptoms or changes in mood.
- Injection Technique: Educate on proper injection techniques and the importance of rotating sites to prevent local reactions.
- Regular Check-Ups: Emphasize the necessity of regular follow-ups for monitoring liver function and overall health.
Conclusion
Avonex (Interferon Beta-1a) 30 mcg Injection is a crucial therapeutic option for managing relapsing forms of multiple sclerosis. By effectively modulating the immune response, it helps reduce the frequency of relapses and slows disease progression. Proper administration, patient education, and regular monitoring are essential for maximizing treatment benefits while minimizing potential adverse effects. Strong communication between patients and healthcare providers plays a vital role in successful MS management.
Yes! I am InterestedRequest A Callback
Azacitidine Injection (Azadine 100mg Injection)
Product Price: Rs 2,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 100 mg |
| Pack Size | 30 ml in 1 Vial |
| Composition | Azacitidine 100mg |
| Brand | Azadine |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Treatment | Myelodysplastic syndrome,chronic myelomonocytic leukaemia,and acute myeloid leukaemia |
Overview
Azacitidine (AZADINE) 100 mg Injection is an innovative antineoplastic agent used primarily for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This cytidine analog works by inhibiting DNA methyltransferase, which leads to the reactivation of silenced genes and promotes normal cell differentiation.
Indications for Use
Azacitidine is primarily indicated for:
- Myelodysplastic Syndromes (MDS): Specifically effective for patients with MDS characterized by a high risk of progression to AML.
- Acute Myeloid Leukemia (AML): Used in certain cases of newly diagnosed AML in elderly patients or those who are not candidates for standard induction chemotherapy.
Mechanism of Action
Azacitidine is a nucleoside analogue that incorporates into RNA and DNA, disrupting normal cellular processes. By inhibiting DNA methyltransferases, it reduces the methylation of DNA, leading to the re-expression of genes that control cell growth and differentiation. This mechanism not only helps to restore normal hematopoiesis but also induces apoptosis in malignant cells.
Dosage and Administration
The recommended dosage of Azacitidine (AZADINE) 100 mg Injection varies based on the patient's specific condition and response to treatment. It is typically administered as a subcutaneous injection once daily for seven days, followed by a 21-day rest period. This cycle may be repeated based on clinical response and tolerability.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Patients often experience gastrointestinal discomfort, manageable with antiemetics.
- Fatigue: Many report feeling tired or weak, a common side effect of chemotherapy.
- Injection Site Reactions: Localized pain, redness, or swelling at the injection site may occur.
Serious side effects can include:
- Bone Marrow Suppression: Regular monitoring of blood counts is essential, as azacitidine can cause neutropenia, thrombocytopenia, and anemia.
- Allergic Reactions: Rarely, severe allergic reactions may occur, necessitating immediate medical attention.
Storage Instructions
Store Azacitidine (AZADINE) 100 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure that the medication is kept out of reach of children.
Patient Counseling Information
Patients receiving Azacitidine should be counseled to:
- Monitor Side Effects: Advise them to report any unusual or severe side effects, particularly signs of infection or bleeding.
- Hydration: Encourage maintaining adequate hydration, especially if experiencing gastrointestinal symptoms.
- Regular Monitoring: Emphasize the importance of regular blood tests to monitor blood counts and liver function throughout treatment.
Conclusion
Azacitidine (AZADINE) 100 mg Injection is a crucial therapeutic option for patients with myelodysplastic syndromes and acute myeloid leukemia. By promoting normal cell differentiation and reducing the burden of malignant cells, it offers hope for improved patient outcomes. Proper administration, vigilant monitoring, and patient education are essential for maximizing treatment benefits while minimizing potential adverse effects. Open communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
Holoxan 1g Injection
Product Price: Rs 550 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 1 g |
| Pack Size | 2 ml in 1 Vial |
| Composition | Ifosfamide 1g |
| Brand Name | Holoxan |
| Manufactured by | Zydus Cadila |
| Treatment | Pancreatic Cancer |
Yes! I am InterestedRequest A Callback
Cytoblastin 10mg Vincristine Injection
Product Price: Rs 200 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 1 mg/ 1ml |
| Packaging Size | 10 mg/10 ml |
| Composition | Vinblastine Sulphate 10 mg |
| Brand Name | Cytoblastin 10 mg |
| Manufactured by | Cipla Ltd |
| Treatment | Non-Hodgkin lymphoma (NHL) |
Overview
Cytoblastin (Vincristine) 10 mg Injection is a widely used chemotherapy drug that belongs to the class of vinca alkaloids. It is primarily indicated for the treatment of various types of cancers, including leukemia, lymphoma, and solid tumors. By inhibiting mitosis, vincristine disrupts cancer cell division, making it an essential component of many cancer treatment regimens.
Indications for Use
Cytoblastin is indicated for:
- Acute Lymphoblastic Leukemia (ALL): Used in combination therapy for treating children and adults.
- Hodgkin's and Non-Hodgkin's Lymphoma: Effective as part of multi-drug regimens in managing these conditions.
- Neuroblastoma: Frequently included in treatment plans for this pediatric cancer.
- Other Malignancies: Utilized in various other cancers as determined by healthcare providers.
Mechanism of Action
Vincristine works by binding to tubulin, a protein that is critical for microtubule formation. This binding inhibits the polymerization of tubulin into microtubules, disrupting the mitotic spindle during cell division. As a result, cancer cells cannot complete mitosis, leading to cell death. Its specific action on rapidly dividing cells makes it particularly effective in oncology.
Dosage and Administration
The recommended dosage of Cytoblastin (Vincristine) 10 mg Injection is typically administered as an intravenous injection. The exact dosage depends on the cancer type, patient’s body surface area, and treatment protocol. It is usually given once a week, and careful monitoring is essential to avoid toxicity.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: These symptoms can often be managed with antiemetic medications.
- Constipation: Vincristine can lead to gastrointestinal disturbances, including constipation.
- Peripheral Neuropathy: Patients may experience tingling, numbness, or pain in the extremities due to nerve damage.
Serious side effects can include:
- Neurotoxicity: Severe neurological symptoms, such as seizures or severe weakness, may occur and require immediate medical attention.
- Bone Marrow Suppression: This can lead to reduced blood cell counts, increasing the risk of infections and bleeding.
Storage Instructions
Store Cytoblastin (Vincristine) 10 mg Injection at room temperature, away from light and moisture. Protect from freezing and ensure it is kept out of reach of children.
Patient Counseling Information
Patients receiving Cytoblastin should be counseled to:
- Report Side Effects: Advise them to notify their healthcare provider of any unusual symptoms, particularly neurological changes or signs of infection.
- Hydration: Encourage fluid intake to help manage side effects and maintain overall health.
- Regular Monitoring: Emphasize the importance of regular blood tests to monitor blood counts and liver function throughout treatment.
Conclusion
Cytoblastin (Vincristine) 10 mg Injection is a critical component in the treatment of various cancers, particularly hematological malignancies. Its unique mechanism of action allows it to effectively disrupt cancer cell division. Proper administration, patient education, and monitoring are essential for maximizing therapeutic benefits while minimizing potential adverse effects. Open communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
Celofos 1 gm Injection
Product Price: Rs 650 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 1 g |
| Pack Size | 1000 mg |
| Composition | Ifosfamide 1 g |
| Brand Name | Celofos |
| Manufactured by | Celon Laboratories Ltd |
| Treatment | Pancreatic cancer |
Yes! I am InterestedRequest A Callback
Pegaspargase 3750 Iu 5ml Injection Hamsyl
Product Price: Rs 20,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 3750 IU / 5 ml |
| Pack Size | 5 ml in 1 Vial |
| Composition | Pegaspargase 3750 IU/5 ml |
| Brand | Hamsyl 3750 IU |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Treatment | Hodgkin's disease |
Overview
Pegaspargase (Hamsyl) 3750 IU/5 mL Injection is a modified form of the enzyme L-asparaginase, used primarily in the treatment of acute lymphoblastic leukemia (ALL). This medication plays a critical role in the management of leukemia, particularly in pediatric patients, by depriving cancer cells of asparagine, an amino acid necessary for their growth and survival.
Indications for Use
Pegaspargase is primarily indicated for:
- Acute Lymphoblastic Leukemia (ALL): Used as part of a multi-agent chemotherapy regimen, especially in newly diagnosed cases and in relapsed leukemia.
Mechanism of Action
Pegaspargase works by hydrolyzing asparagine in the bloodstream. Many leukemia cells are unable to synthesize asparagine due to a lack of the enzyme asparagine synthetase. By reducing the levels of circulating asparagine, Pegaspargase effectively starves these cancer cells, leading to their apoptosis (programmed cell death). The pegylation of the enzyme prolongs its half-life, allowing for less frequent dosing compared to standard L-asparaginase.
Dosage and Administration
The recommended dosage of Pegaspargase (Hamsyl) 3750 IU/5 mL Injection is typically administered intramuscularly or intravenously, depending on the treatment protocol. Dosage is determined by the healthcare provider based on the patient's body surface area and specific treatment regimen. Regular monitoring of liver function and coagulation parameters is essential, as the drug can impact these systems.
Potential Side Effects
Common side effects may include:
- Hypersensitivity Reactions: Allergic reactions may occur, including rashes, itching, or more severe anaphylactic responses.
- Pancreatitis: Inflammation of the pancreas can occur, leading to abdominal pain and other gastrointestinal symptoms.
- Thrombosis: There is a risk of thrombotic events, particularly in patients with pre-existing risk factors.
Serious side effects can include:
- Liver Toxicity: Elevated liver enzymes may indicate hepatotoxicity, requiring close monitoring.
- Bleeding or Clotting Disorders: Due to its effects on coagulation factors, patients may experience bleeding or thrombosis.
Storage Instructions
Store Pegaspargase (Hamsyl) 3750 IU/5 mL Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure that the medication is kept out of reach of children.
Patient Counseling Information
Patients receiving Pegaspargase should be counseled to:
- Report Side Effects: Advise them to notify their healthcare provider of any unusual reactions, particularly signs of allergic reactions or abdominal pain.
- Regular Monitoring: Emphasize the importance of regular blood tests to monitor liver function, blood counts, and signs of thrombosis or bleeding.
- Hydration: Encourage adequate fluid intake to support overall health during treatment.
Conclusion
Pegaspargase (Hamsyl) 3750 IU/5 mL Injection is a crucial component in the treatment of acute lymphoblastic leukemia. By targeting the metabolic needs of cancer cells, it effectively contributes to improved outcomes in leukemia management. Proper administration, patient education, and close monitoring are essential for maximizing therapeutic benefits while minimizing potential adverse effects. Open communication between patients and healthcare providers is fundamental for successful cancer care.
Yes! I am InterestedRequest A Callback
Azacitidine Injection (Myaza Injection 100mg)
Product Price: Rs 3,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Type | Vial |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Azacitidine 100mg |
| Brand | Myaza 100 mg |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Treatment | Blood cancer |
Yes! I am InterestedRequest A Callback
Pemnat 500 Mg Injection
Product Price: Rs 800 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 500 mg |
| Pack Size | 1 injection in 1 Vial |
| Composition | Pemetrexed 500 mg |
| Brand | Pemnat |
| Manufacturer | Natco Pharma Ltd |
| Treatment | Non-small cell lung cancer and malignant pleural mesothelioma |
Overview
Pemnat (Pemetrexed) 500 mg Injection is a key chemotherapeutic agent used primarily for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. As an antimetabolite, pemetrexed disrupts cancer cell growth by inhibiting folate-dependent metabolic processes crucial for DNA synthesis.
Indications for Use
Pemnat is primarily indicated for:
- Non-Small Cell Lung Cancer (NSCLC): Often used in combination with other chemotherapy agents for patients with advanced or metastatic disease.
- Malignant Pleural Mesothelioma: Utilized as part of a treatment regimen for patients who are not candidates for curative surgery.
Mechanism of Action
Pemetrexed works by inhibiting multiple enzymes involved in the folate pathway, particularly thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This inhibition disrupts the synthesis of nucleotides necessary for DNA and RNA production, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Dosage and Administration
The recommended dosage of Pemnat (Pemetrexed) 500 mg Injection is typically administered intravenously, with the dosage adjusted based on the patient’s body surface area and overall health status. It is usually given every three weeks, often in combination with cisplatin for enhanced efficacy. Pre-medication with folic acid and vitamin B12 is recommended to reduce the risk of hematologic and gastrointestinal toxicity.
Potential Side Effects
Common side effects may include:
- Nausea and Vomiting: Patients may experience gastrointestinal discomfort, which can often be managed with antiemetic medications.
- Fatigue: A common symptom during treatment, patients may feel unusually tired or weak.
- Bone Marrow Suppression: This may lead to decreased blood cell counts, increasing the risk of infections, anemia, and bleeding.
Serious side effects can include:
- Hypersensitivity Reactions: Patients should be monitored for allergic reactions, which may include rashes or difficulty breathing.
- Interstitial Lung Disease: Rarely, pemetrexed may cause lung toxicity, necessitating close monitoring of respiratory symptoms.
Storage Instructions
Store Pemnat (Pemetrexed) 500 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure it is kept out of reach of children.
Patient Counseling Information
Patients receiving Pemnat should be counseled to:
- Report Side Effects: Advise them to notify their healthcare provider of any unusual reactions or severe symptoms, particularly respiratory issues or allergic reactions.
- Regular Monitoring: Stress the importance of routine blood tests to monitor blood cell counts and liver function throughout the treatment course.
- Hydration and Nutrition: Encourage patients to maintain good hydration and nutritional support during treatment.
Conclusion
Pemnat (Pemetrexed) 500 mg Injection is an essential treatment for non-small cell lung cancer and malignant pleural mesothelioma. By targeting crucial metabolic pathways in cancer cells, it effectively inhibits tumor growth and improves patient outcomes. Proper administration, patient education, and monitoring are critical for maximizing therapeutic benefits while minimizing potential adverse effects. Open communication between patients and healthcare providers is vital for successful cancer treatment.
Yes! I am InterestedRequest A Callback
Carzomib Carfilzomib 60mg Injection
Product Price: Rs 12,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 60 mg |
| Packaging Type | Vial |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Carfilzomib 60 mg/vial |
| Brand | Carzomib |
| Manufacturer | Hetero Healthcare Limited |
| Treatment | Multiple myeloma |
Overview
Carzomib (Carfilzomib) 60 mg Injection is a potent proteasome inhibitor used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. Carfilzomib targets and inhibits the proteasome, leading to an accumulation of pro-apoptotic factors and ultimately inducing cancer cell death. It is particularly effective in patients who have received prior therapies.
Indications for Use
Carzomib is indicated for:
- Multiple Myeloma: Used in combination with other medications for adult patients who have received at least one prior therapy. It is effective in both newly diagnosed and relapsed/refractory cases.
Mechanism of Action
Carfilzomib works by selectively inhibiting the proteasome, a complex responsible for degrading ubiquitinated proteins. This inhibition disrupts various cellular processes, including the regulation of the cell cycle and apoptosis, leading to the death of myeloma cells. By targeting the proteasome, Carzomib enhances the effectiveness of other anti-cancer therapies and contributes to improved patient outcomes.
Dosage and Administration
The standard dosing regimen for Carzomib (Carfilzomib) 60 mg Injection involves administering the drug intravenously. The recommended dose typically starts at 20 mg/m² on days 1 and 2 of a 28-day cycle, escalating to 60 mg/m² for subsequent doses. Healthcare providers will tailor the dosage based on the patient's condition and response to treatment.
Potential Side Effects
Common side effects may include:
- Fatigue: Many patients report feelings of tiredness or weakness during treatment.
- Nausea and Diarrhea: Gastrointestinal disturbances are common but manageable with supportive care.
- Thrombocytopenia: A decrease in platelet count, increasing the risk of bleeding.
Serious side effects can include:
- Cardiac Issues: Patients may experience heart problems, including heart failure and arrhythmias.
- Renal Impairment: Monitoring kidney function is essential, as Carfilzomib can affect renal health.
Storage Instructions
Store Carzomib (Carfilzomib) 60 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure it is kept out of reach of children.
Patient Counseling Information
Patients receiving Carzomib should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual symptoms, particularly signs of cardiac issues or bleeding.
- Regular Monitoring: Emphasize the importance of routine blood tests to monitor blood counts and kidney function.
- Hydration and Nutrition: Encourage adequate fluid intake and a balanced diet to help manage treatment-related side effects.
Conclusion
Carzomib (Carfilzomib) 60 mg Injection is a critical treatment option for multiple myeloma, offering a targeted approach that enhances the effectiveness of traditional therapies. Its unique mechanism of action, combined with careful patient management, can lead to improved outcomes for individuals with this challenging disease. Proper administration, patient education, and regular monitoring are essential components of successful treatment.
Yes! I am InterestedRequest A Callback
Alphalan 50mg Injection
Product Price: Rs 1,050 / BottleGet Best Price
Minimum Order Quantity: 10 Bottle
Product Brochure
Product Details:
| Strength | 50mg |
| Dose/Strenght | 50 mg |
| Pack Size | 50 mg in 1 Vial |
| Composition | Melphalan 50 mg |
| Brand Name | Alphalan 50 mg |
| Manufactured by | Natco Pharma Ltd |
| Treatment | Multiple myeloma,Ovarian cancer |
Overview
Alphalan (Melphalan) 50 mg Injection is a powerful alkylating agent used primarily in the treatment of multiple myeloma and ovarian cancer. It works by interfering with DNA replication and repair, leading to cancer cell death. Melphalan is an essential part of combination chemotherapy regimens aimed at improving patient outcomes.
Indications for Use
Alphalan is indicated for:
- Multiple Myeloma: Effective as part of a combination therapy for patients with this blood cancer, particularly in conjunction with other agents.
- Ovarian Cancer: Used in patients with advanced disease, especially when other treatment options have been exhausted.
Mechanism of Action
Melphalan acts by forming covalent bonds with DNA, resulting in cross-linking of the DNA strands. This process inhibits DNA replication, disrupts cell division, and induces apoptosis (programmed cell death) in malignant cells. Its ability to target rapidly dividing cells makes it effective against various types of cancer.
Dosage and Administration
The recommended dosage for Alphalan (Melphalan) 50 mg Injection is typically determined by the healthcare provider based on the type of cancer, treatment goals, and patient characteristics. It may be administered as an intravenous injection or infusion, often as part of a combination chemotherapy regimen. Close monitoring during treatment is crucial to adjust dosages and manage side effects.
Potential Side Effects
Common side effects may include:
- Bone Marrow Suppression: This can lead to anemia, leukopenia, and thrombocytopenia, increasing the risk of infections and bleeding.
- Nausea and Vomiting: Gastrointestinal upset is common but can often be managed with appropriate medications.
- Fatigue: Many patients experience tiredness, which can affect their daily activities.
Serious side effects can include:
- Infections: Due to decreased immune function, patients are at a higher risk for infections.
- Liver Toxicity: Monitoring liver function is important, as Melphalan can affect liver enzymes.
Storage Instructions
Store Alphalan (Melphalan) 50 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure it is kept out of reach of children.
Patient Counseling Information
Patients receiving Melphalan should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual symptoms, particularly signs of infection or bleeding.
- Regular Monitoring: Emphasize the importance of routine blood tests to monitor blood counts and liver function.
- Hydration and Nutrition: Encourage a well-balanced diet and adequate fluid intake to help manage side effects.
Conclusion
Alphalan (Melphalan) 50 mg Injection is an important therapeutic option for treating multiple myeloma and ovarian cancer. Its mechanism of action effectively targets cancer cells, while careful administration and monitoring can help minimize side effects. Open communication between patients and healthcare providers is vital for optimizing treatment outcomes and ensuring comprehensive cancer care.
Yes! I am InterestedRequest A Callback
Taxonab 100Mg Paclitaxel
Product Price: Rs 17,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Packaging Type | Vial |
| Strength | 100 mg |
| Manufacturer | Zydus Ingenia |
| Pack Type | 1 Injection in 1 Vial |
| Composition | Paclitaxel (Protein-Bound Particales) 100 mg |
| Brand | Taxonab |
| Treatment | Ovarian cancer,breast cancer,non-small cell lung cancer |
Overview
Taxonab (Paclitaxel) 100 mg Injection is a widely used chemotherapy agent in the treatment of various cancers, including breast, ovarian, and lung cancers. As a taxane, it works by inhibiting cell division, leading to the death of rapidly dividing cancer cells.
Indications for Use
Taxonab is indicated for:
Breast Cancer: Used in both adjuvant and metastatic settings, often in combination with other chemotherapy agents.
Ovarian Cancer: Effective for treating both early and advanced stages of ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Administered with cisplatin for advanced NSCLC.
Kaposi’s Sarcoma: Utilized in patients with AIDS-related Kaposi's sarcoma who have not responded to other treatments.
Mechanism of Action
Paclitaxel binds to the protein tubulin, promoting the formation of microtubules and stabilizing them. This action disrupts normal mitotic spindle function, effectively halting cell division and leading to apoptosis (programmed cell death) in cancer cells. By preventing the breakdown of microtubules, Taxonab causes accumulation in the G2/M phase of the cell cycle, which is crucial for successful division.
Dosage and Administration
The dosage of Taxonab (Paclitaxel) 100 mg Injection is individualized based on cancer type and patient characteristics. It is typically administered intravenously, with the infusion rate monitored to minimize potential side effects. Common schedules may involve administration every three weeks or weekly, depending on the treatment protocol.
Potential Side Effects
Common side effects may include:
Nausea and Vomiting: Gastrointestinal symptoms can often be managed with appropriate antiemetics.
Bone Marrow Suppression: Patients may experience decreases in white blood cells, red blood cells, and platelets, increasing the risk of infections.
Neuropathy: Some report tingling, numbness, or pain in hands and feet due to nerve damage.
Hair Loss: Temporary alopecia is common with this treatment.
Serious side effects can include severe allergic reactions, liver toxicity, and cardiac effects, necessitating regular monitoring.
Storage Instructions
Store Taxonab (Paclitaxel) 100 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Ensure the medication remains in its original packaging until use to maintain stability.
Patient Counseling Information
Patients receiving Taxonab should be advised to:
Report Side Effects: Notify healthcare providers of any unusual reactions, particularly neurological symptoms or signs of infection.
Adhere to Treatment: Stress the importance of following the prescribed regimen and attending all scheduled appointments for monitoring.
Maintain Hydration: Encourage adequate fluid intake before and after the infusion.
Conclusion
Taxonab (Paclitaxel) 100 mg Injection is a vital chemotherapy option for various malignancies, including breast, ovarian, and lung cancers. Its mechanism of inhibiting cell division makes it an essential part of many treatment regimens. Proper administration, monitoring, and patient education are critical to maximizing treatment effectiveness. Effective communication between patients and healthcare providers is key to ensuring optimal cancer care.
Yes! I am InterestedRequest A Callback
Cizumab 400 Mg Injection
Product Price: Rs 25,000 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Packaging Type | Box |
| Composition | Bevacizumab 400 mg/16 ml |
| Brand Name | Cizumab 400 |
| Manufacturer | Hetero Drugs Ltd |
| Treatment | Colon and rectum Cancer,Ovarian cancer,Cervical cancer,Kidney cancer,Brain tumor |
Overview
Cizumab (Bevacizumab) 400 mg Injection is a monoclonal antibody that plays a crucial role in the treatment of various cancers by targeting vascular endothelial growth factor (VEGF). By inhibiting the formation of blood vessels that supply tumors, Cizumab helps to starve cancer cells of the nutrients and oxygen they need to grow.
Indications for Use
Cizumab is indicated for:
- Metastatic Colorectal Cancer: Often used in combination with chemotherapy for patients with advanced disease.
- Non-Small Cell Lung Cancer (NSCLC): Indicated for patients with locally advanced or metastatic disease, in conjunction with chemotherapy.
- Breast Cancer: Used in combination with chemotherapy for metastatic cases.
- Renal Cell Carcinoma: Effective in treating advanced renal cell carcinoma as part of a combination regimen.
- Ovarian Cancer: Used for patients with recurrent disease, in combination with chemotherapy.
Mechanism of Action
Bevacizumab works by binding to VEGF, preventing it from interacting with its receptors on endothelial cells. This inhibition blocks the angiogenesis process (formation of new blood vessels), effectively reducing tumor growth and metastasis. By limiting the blood supply, Cizumab enhances the effectiveness of other cancer treatments and helps to shrink tumors.
Dosage and Administration
The dosage of Cizumab (Bevacizumab) 400 mg Injection is individualized based on the specific type of cancer and the patient’s overall condition. It is administered as an intravenous infusion, typically every two to three weeks. Healthcare providers will monitor patients closely during and after infusion to manage any potential side effects.
Potential Side Effects
Common side effects may include:
- Hypertension: Elevated blood pressure may occur and requires monitoring and management.
- Fatigue: Many patients experience fatigue that can impact daily activities.
- Gastrointestinal Issues: Symptoms such as nausea, vomiting, and diarrhea can occur.
- Wound Healing Complications: Increased risk of delayed wound healing after surgery.
Serious side effects can include severe allergic reactions, gastrointestinal perforations, and thromboembolic events (blood clots), necessitating careful monitoring during treatment.
Storage Instructions
Store Cizumab (Bevacizumab) 400 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to ensure stability and effectiveness.
Patient Counseling Information
Patients receiving Cizumab should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly gastrointestinal issues or signs of hypertension.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage regular blood pressure checks and reporting any changes in health status.
Conclusion
Cizumab (Bevacizumab) 400 mg Injection is a vital treatment option in oncology, particularly for various solid tumors. Proper administration, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for effective cancer management.
Yes! I am InterestedRequest A Callback
Paclitaxel (Pacshil 260 Injection)
Product Price: Rs 2,500 / VialGet Best Price
Minimum Order Quantity: 10 Vial
Product Brochure
Product Details:
| Strength | 260 mg |
| Pack Size | 43.4 ml |
| Pack Type | Vial |
| Composition | Paclitaxel 260mg |
| Brand | Pacshil 260 |
| Manufactured by | Shilpa Medicare Limited |
| Treatment | Breast cancer,Non-small cell lung cancer,Pancreatic cancer |
Overview
Paclitaxel (Pacshil 260 Injection) is a widely used chemotherapy medication derived from the bark of the Pacific yew tree (Taxus brevifolia). It is a key agent in the treatment of various cancers, including breast, ovarian, lung, and other solid tumors. Paclitaxel works by disrupting the normal function of microtubules in the cell, inhibiting cell division and leading to cancer cell death.
Indications for Use
Paclitaxel is indicated for:
- Breast Cancer: Used in both early-stage and metastatic HER2-negative breast cancer, often in combination with other chemotherapy agents.
- Ovarian Cancer: Effective in treating both advanced and recurrent ovarian cancer, frequently used as part of a combination regimen.
- Non-Small Cell Lung Cancer: Administered as part of combination therapy for advanced stages.
- Other Cancers: May also be used in the treatment of pancreatic cancer and Kaposi's sarcoma.
Mechanism of Action
Paclitaxel acts by stabilizing microtubules and preventing their disassembly during mitosis. This inhibition of the normal breakdown of the mitotic spindle halts cell division, effectively leading to cell death. By disrupting the cell cycle, Paclitaxel targets rapidly dividing cancer cells, making it an effective treatment option.
Dosage and Administration
The dosage of Paclitaxel (Pacshil 260 Injection) is individualized based on the type of cancer, patient condition, and treatment plan. It is typically administered intravenously over a period of 3 to 24 hours, depending on the specific protocol. Pre-medication with corticosteroids, antihistamines, and antiemetics may be recommended to minimize the risk of allergic reactions and side effects.
Potential Side Effects
Common side effects may include:
- Bone Marrow Suppression: Leading to decreased blood cell counts, increasing the risk of infections and anemia.
- Peripheral Neuropathy: Patients may experience tingling or numbness in the extremities.
- Gastrointestinal Issues: Nausea, vomiting, and diarrhea are commonly reported.
- Fatigue: A prevalent side effect that can impact daily activities.
Serious side effects can include severe allergic reactions, liver enzyme abnormalities, and cardiac issues, highlighting the importance of close monitoring during treatment.
Storage Instructions
Store Paclitaxel (Pacshil 260 Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Always keep the medication in its original packaging until use to maintain its stability and effectiveness.
Patient Counseling Information
Patients receiving Paclitaxel should be advised to:
- Report Side Effects: Notify healthcare providers of any unusual or severe symptoms, particularly those related to allergic reactions or peripheral neuropathy.
- Adhere to Treatment: Emphasize the importance of following the prescribed regimen and attending all follow-up appointments.
- Regular Monitoring: Encourage routine blood tests to monitor blood cell counts and liver function.
Conclusion
Paclitaxel (Pacshil 260 Injection) is a critical chemotherapy agent used in the treatment of various cancers, particularly breast and ovarian cancers. Proper administration, monitoring, and patient education are essential for optimizing treatment efficacy and minimizing adverse effects. Open communication between patients and healthcare providers is vital for effective cancer management.
Yes! I am InterestedRequest A Callback
View More